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In 1999 an exotic mosquito-borne virus, West Nile virus (WNV), was recognized for the 
first time in the US, causing an outbreak of meningoencephalitis in people and a large-
scale die-off in birds. At the time, there was no federal funding to directly support state 
and local surveillance for mosquito-borne illness and, consequently, there was no 
nationally coordinated arboviral surveillance system that could be mobilized to respond. 
There was only the patchy presence of home-grown state and locally-based surveillance 
and control systems established to cope with the annual threat in some states of outbreaks 
of St Louis encephalitis (SLE), eastern equine encephalitis (EEE), sporadic cases of other 
mosquito-borne viral disease and regular identification of persons infected with dengue 
virus and malaria acquired outside the US but with potential for local transmission. 
   
While the initial surveillance and prevention response to WNV in 1999 in New York, 
New Jersey and Connecticut was accomplished by diverting staff hired to do other 
surveillance work, authorities anticipated that WNV could become endemic in those first 
affected areas and spread, posing a threat to more of the country. Beginning in 2000, 
Congress appropriated annual funding for WNV surveillance and prevention activities for 
the first affected states and, over the next few years as WNV spread across the US, to all 
states and six large city/county health departments through the Centers for Disease 
Control and Prevention (CDC) Epidemiology and Laboratory Capacity (ELC) 
cooperative agreements for emerging infectious diseases. Funding was accompanied by 
development of guidelines for WNV surveillance and prevention and development of 
ArboNet, a distributed national surveillance network coordinated by CDC.  
 
By 2004, WNV had spread to and become endemic in all 48 contiguous states, and 
federal support to state and local jurisdictions for WNV surveillance and prevention 
reached its highest sustained level, approximately $24 million per year.  A 2004 
assessment conducted by the Council of State and Territorial Epidemiologists (CSTE) 
found that WNV surveillance and control programs were well developed in all states and 
major cities receiving specific ELC funding for that purpose. CSTE attributed the success 
of this public health effort to ELC funding and CDC leadership and coordination and 
declared that a national WNV surveillance program had been established. Based on the 
assessment results, CSTE recommended that ELC funding for WNV surveillance and 
control be sustained, with consideration for flexibility to use these funds to address 
vector-borne and arboviral diseases more broadly. Since then, funding guidelines have 
become more flexible, enabling surveillance for 11 domestic arboviruses (including 
WNV) and four travel-associated viruses (including dengue). However, despite 
recognition of a shared local, state and national interest in arbovirus control, funding for 
this purpose through the ELC cooperative agreement has gradually dropped to less than 
$10 million per year—a more than 60% decrease since 2004. 
 
In August 2013, CSTE—with technical input from CDC and assistance from the National 
Association of City and County Health Officers (NACCHO), the Association of State and 
Territorial Health Officials (ASTHO) and the Association of Public Health Laboratories 
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(APHL)—assessed state health departments and 30 local health departments (LHDs) with 
either direct access to ELC funding or a high WNV threat level based on previous 
experience to describe:  (a) the jurisdictions’ current capacity to conduct surveillance for 
WNV and other mosquito-borne viral infections, (b) how current dedicated personnel are 
funded and (c) how capacity has changed since peak funding in 2004. The assessment 
partners shared an interest in the long-term sustainability of the national arboviral 
surveillance system (ArboNet) created in response to WNV. 
 
The assessment instrument was developed in May and June 2013. The 2004 assessment 
was used as a template to enable comparison. The earlier assessment used published CDC 
guidelines for WNV surveillance to identify and measure 21 indicators of capacities 
related to human, equine, avian and mosquito infection; laboratory capacity and 
programmatic prevention activities. New questions were added in 2013 to assess the 
number and sources of funding of staff dedicated to WNV surveillance, their functional 
role, needs for additional staff to achieve “full epidemiology and laboratory capacity to 
conduct WNV and other mosquito-borne disease surveillance” and changes (if any) made 
in the past five years in response to reduced ELC funding. Respondents were instructed 
to answer questions based on program activities in 2012. All 50 states, all six LHDs with 
ELC funding support and 15 of 24 LHDs with no direct ELC support submitted 
responses.  
 
There are six major findings.  
 
1. All 48 contiguous states retain some capacity for WNV surveillance.  Surveillance 
capacity ranges widely among the states, from a minimal ability to diagnose and 
report human WNV cases to ability for more comprehensive surveillance, including 
monitoring WNV activity in mosquitoes (80%), dead birds (39%) and sentinel 
chickens (10%). 
2. Surveillance capacity has decreased since 2004, despite the endemicity of WNV, 
recurring large outbreaks with substantial morbidity and mortality and a pressing 
need to monitor other arboviruses that pose growing threats. The number of staff 
working at least half-time on WNV surveillance in states has dropped by 41%. The 
percentage of states conducting mosquito surveillance has dropped from 96% to 80%. 
The percentage conducting avian mortality surveillance has dropped from 98% to 
39%. More than half of states (58%) have reduced mosquito trapping activities, and 
68% have reduced mosquito testing. Alarmingly, laboratory and 
mosquito/environmental surveillance capacities for WNV have reached a tipping 
point, where further reductions in capacity will likely result in their loss entirely in 
some states.  
3. Although many state and LHDs have made a substantial funding investment in WNV 
surveillance and control, some are entirely dependent on ELC WNV funding. Yet in 
all jurisdictions, ELC WNV funding remains critical to sustain current capacity, 
including in LHDs with no direct ELC funding but a historically high WNV burden. 
In addition to losing dedicated staff, ELC funding cuts have resulted in reduced 
mosquito surveillance (trapping, testing or both) in 70% of states and 75% of LHDs, 
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elimination of avian mortality surveillance in most jurisdictions and reduced testing 
of human specimens for WNV (and potentially other arboviruses) in 46% of states.  
4. The capacity to conduct surveillance for other mosquito-borne viruses is patchy, with 
a few states having high-level capacity, but many having little to none. In particular, 
although many state public health laboratories have the capability to test for SLE 
(79%), EEE (59%), WEE (39%) or LaCrosse (42%) viruses, routine testing for these 
viruses by state laboratories in meningoencephalitis patient specimens actually occurs 
much less frequently than for WNV (SLE 73%, EEE 27%, WEE 9%, LaCrosse 8%). 
In part, this disparity results from inadequate laboratory staffing. Further, only nine 
state laboratories perform testing for dengue, four for Powassan, and two each for 
Chikungunya and Colorado tick fever viruses. 
5. LHDs in areas with a historically high WNV burden play a key role in mosquito 
surveillance and control and in supporting surveillance for human WNV disease. 
They average more than double the amount of staffing per health department than 
state health departments for mosquito surveillance and for human disease 
surveillance. However, even in areas with a historically high WNV burden, current 
capacities in non-ELC LHDs are lower than those in LHDs that receive direct ELC 
funding. Although all ELC-funded LHDs conduct mosquito surveillance, only 67% of 
those without ELC-funding do so.  
6. Most states and ELC-funded local health departments need additional support to be 
able to fully conduct surveillance for WNV and other mosquito-borne viruses 
(including dengue). Specifically, support is needed for an additional 137.6 FTE staff, 
a 58% increase in current staffing levels. An additional 49 FTE staff are needed in the 
15 responding LHDs with a historically high WNV burden but no direct ELC 
funding, mostly for mosquito surveillance. 
 
 
Based on these findings, CSTE—supported by ASTHO, NACCHO and APHL—
recommends CDC take the following actions. 
 
 At a minimum, assure that current state and local health department capacity for 
WNV surveillance is maintained to assure  not just state-level, but a national 
infrastructure for WNV and arboviral surveillance. Sufficient funding through the 
ELC cooperative agreement is needed to achieve this goal; level ELC funding will 
result in further erosion of capacity.  
 Secure additional support to distribute through the ELC cooperative agreement to: (a) 
expand mosquito-based surveillance in metropolitan areas with a historically large 
WNV disease burden (as many have reduced mosquito surveillance and a third have 
no mosquito surveillance capacity whatsoever) and (b) build sufficient capacity to 
conduct surveillance in all states for other endemic arboviruses (e.g., EEE, SLE, 
WEE, LaCrosse, Powassan viruses) and for emerging arboviral threats (e.g., dengue, 
Chikungunya, Japanese encephalitis, Zika, Heartland viruses). This includes having 
the public health laboratory capacity in most states to assure they routine test for and 
monitor the incidence of other arboviruses as is now done for WNV.   
 Contingent on the availability of additional funding, expand core ELC cooperative 
agreement objectives to include the following enhanced capacities to monitor 
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endemic arboviruses and to detect and respond to the introduction of exotic 
arboviruses: 
o All ELC recipients should have WNV surveillance and control plans, and as 
appropriate to local risk, surveillance and control plans for other arboviruses. 
o Mosquito-based surveillance should be included in the programs for 
metropolitan areas with historically high WNV burden. 
o Diagnostic human specimens (cerebrospinal fluid and sera) submitted for 
WNV testing should be routinely tested for other endemic and exotic 
arboviruses, depending on the clinical syndrome, exposure history and local 
vector populations.  
Without additional funding, however, ELC-funded jurisdictions cannot be 









West Nile virus (WNV) was first documented in the US in 1999 in New York City and 
surrounding counties and states.
1,2
 By the end of 2004, it had become endemic throughout 
the contiguous states.
3
 It is now the most common mosquito-borne disease on the US 
mainland. An average of 1,137 cases of neuroinvasive disease (range, 386-2,873 cases) 
and 110 deaths (range, 32-286 deaths) occurred each year between 2005 and 2012, with 




Beyond these numbers, authorities estimate that for every person who develops 
neuroinvasive disease, there are at least 100 additional cases of WNV infection, many 
with febrile illness.  Some WNV patients develop a polio-like syndrome, many suffer 
months-long debilitation, and some never return to pre-infection levels of functioning.
5
 
Moreover, the acutely infected can infect others through blood and organ donations, often 
with devastating consequences to the recipient.
 6,7
 This possibility has led to routine 
screening of the blood supply for WNV and increased awareness of the need to screen 
organ donors, when feasible.  
 
Of particular concern, WNV unpredictably causes intense outbreaks affecting thousands 
of individuals over a short period of time. Yet, infection and outbreaks are potentially 
preventable through individual behavior change (e.g., staying indoors when mosquitoes 
are most active) and efforts to reduce vector mosquito populations at times of peak threat. 
Both personal and population-level prevention activities depend upon near real-time 
surveillance data, including whether WNV is present in vector mosquito species, 
numbers of vector mosquitoes, infection level in vector mosquitoes, and levels of disease 
in humans and sentinel animals, such as horses and birds.  
In 1999, there was no federal public health funding to directly support state or local 
mosquito-borne disease surveillance and, consequently, no nationally coordinated 
arboviral surveillance system that could be mobilized to respond to the nation’s first 
WNV outbreaks. There was only the patchy presence of home-grown state and locally-
based surveillance and control systems established to cope with the annual threat in some 
states of outbreaks of St Louis encephalitis (SLE), eastern equine encephalitis (EEE), 
sporadic cases of other mosquito-borne viral disease and regular identification of persons 
infected with dengue virus and malaria acquired outside the country, but with potential 
for local transmission. Few states had dedicated epidemiologic and laboratory staff to 
mount a sustained emergency WNV response without compromising other public health 
surveillance programs. While the initial surveillance and prevention response in New 
York, New Jersey and Connecticut was accomplished by diverting staff hired to do other 
surveillance work, authorities anticipated that WNV could become endemic in those first 
affected areas and spread, posing a threat to more of the country. 
Beginning in 2000, Congress appropriated annual funding for WNV surveillance and 
prevention activities for the first affected states and, over succeeding years, to all states 
and six large city/county health departments through the Centers for Disease Control and 
 9 
Prevention (CDC) Epidemiology and Laboratory Capacity (ELC) cooperative agreements 
for emerging infectious diseases. Funding was accompanied by development of 
guidelines for WNV surveillance and prevention and development of ArboNet, a 
distributed national surveillance network coordinated by CDC. By 2004, federal funding 
to support state and local WNV surveillance and prevention reached its highest sustained 
level, approximately $24 million per year.  A 2004 assessment conducted by the Council 
of State and Territorial Epidemiologists (CSTE) found that WNV surveillance and 
control programs were well developed in all states and major cities receiving specific 
ELC funding for that purpose. CSTE attributed the success of this public health 
achievement to ELC funding and CDC leadership and coordination and declared that a 
national WNV surveillance program had been established. Based on the assessment 
results, CSTE recommended that ELC funding for WNV surveillance and control be 
sustained, with consideration for flexibility to use these funds to address vector-borne and 
arboviral diseases more broadly. Since then, funding guidelines have become more 
flexible, enabling surveillance for 11 domestic arboviruses (including WNV) and four 
travel-associated viruses (including dengue). 
 
Since 2006, however, this federal funding 
has decreased each year, reaching a low of 
$9,340,637 in 2012, ironically, the year of 
highest WNV incidence since 2003 (See 
Figure 1).  Past funding cuts and future 
fiscal uncertainty raise concerns about the 
sustainability of current capacity for 
human WNV surveillance; mosquito 
detection, testing and control; supportive 
laboratory services; and prevention 
messaging, given that they were largely 
developed with federal funding. Indeed 
the entire national arboviral surveillance system may be threatened.  
 
Another concern is the documented expansion of the range of several historically tropical 
Aedes mosquito species—including Aedes aegypti and Aedes albopictus—capable of 
transmitting viral diseases of public health importance. These species are competent 
vectors for endemic arboviruses, such as EEE, and for exotic viruses, such as dengue, 
Chikungunya and yellow fever. In fact, public health officials and researchers are 
documenting a growing number of introductions of dengue fever virus into the US, as 
well as episodes of local disease transmission.
11,12
 Authorities worry that US states will 
have increasing difficulty dealing with the growing threat of dengue and other mosquito-
borne diseases if the state and local public health infrastructure built to respond to WNV 
is eroded.   
 
In May 2013, CSTE initiated efforts to assess the current surveillance and prevention 
capacity for WNV and other mosquito-borne viruses in state and select LHDs. The 
association had four broad objectives: (a) to assess current state and select LHD capacity 
to conduct surveillance for WNV and other mosquito-borne viruses, (b) to compare 
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staffing and capacity for WNV surveillance in 2004 and 2012; (c) to determine how state 
and large city/county health departments are currently funding, staffing and conducting 
WNV surveillance and control activities, and (d) to document health department staffing 




A working group was established in May 2013 to develop the assessment tools (See 
Appendices 2 and 3). The working group included representatives from CSTE national 
headquarters, CDC Division of Vector-Borne Diseases (DVBD), ASTHO, NACCHO and 
APHL, as well as a CSTE consultant and a consultant from Emory University. The 2004 
assessment instrument was used as a starting point to enable comparison with its findings. 
The 2004 assessment included 21 indicators—taken from CDC’s 2003 WNV 
guidelines
9
—of a range of capacities related to human, equine, avian and mosquito 
infection and disease surveillance; laboratory diagnostic testing; and program prevention 
activities. Questions no longer relevant in 2012 were eliminated (e.g., some details about 
avian mortality and equine surveillance) and new questions added, based in part on a 
draft of new WNV surveillance, prevention and control guidance.
10
 In addition, questions 
were added to assess specific staffing needs, desired and actual state role in support of 
LHD mosquito control activities, presence of Aedes aegypti and associated dengue 
preparedness, and how reductions in funding in the past five years have affected WNV 
surveillance activities. Separate questionnaires were developed for large city/county 
health departments in which some of the state questions were modified, particularly to 
reflect the primary LHD role in mosquito surveillance and control. Respondents were 
instructed to answer questions based on program activities in 2012.  
 
The assessment tools were completed in June and piloted during July in seven states and 
four LHDs.  Based on feedback, several questions were reworded for clarity. In early 
August, a pdf file of the state assessment was sent via e-mail to the state epidemiologist 
in all 50 state health departments. Instructions stated that the “most appropriate staff 
person in your agency” be the key respondent and obtain relevant information from 
laboratory and mosquito surveillance and control staff in order to complete the 
assessment online. The online assessment used Epi Info
TM
 Web Survey system.  
 
A similar process was used to distribute the local assessment questionnaire to 30 large 
city/county health departments, although the contact person in many cases was the health 
officer in the absence of a city/county epidemiologist. City/county health departments 
were selected based on meeting at least one of three criteria:  (a) receiving supplemental 
WNV surveillance funding through the ELC grant (n=6), (b) having had at least 100 
cumulative reported cases of WNV neuroinvasive disease from 1999 through 2012 
(n=22, excluding four of the ELC recipients), or (c) having had local dengue transmission 
(n=2, neither met the other criteria).   
 
CSTE staff entered data that were not submitted online, including revised responses to 
questions that were unclear to health department staff who participated in the pilot 
assessment. Data from the state assessment and from the large city/county health 
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department assessment were analyzed separately. Results were tallied in aggregate and 
separately for state health departments and LHDs.  In addition, state respondents were 
grouped into categories—and data analyzed separately for each—based on (a) state 
population (quartiles), (b) geographic region (five different regions), (c) magnitude of the 
state’s 2012 CDC WNV surveillance funding and (d) state burden of WNV in 2008-2012 
(See Appendix 1). Capacity for selected surveillance activities in 2012 was compared 
between states reporting a need for additional surveillance staff and those not reporting 
such a need. 
 
LHD respondents were grouped into two categories—and data analyzed separately for 
each—based on receipt or non-receipt of direct CDC ELC cooperative agreement funding 
for WNV and other mosquito-borne virus surveillance.  
 
Responses to some questions were left blank. For questions relating to staffing and 
staffing needs, CSTE assumed blank responses indicated a lack of staff in the given 
response category. Thus, responses from all states were counted.  For all other questions, 
a blank response was assumed to be a missing response and states with no response were 
not counted.  
 
Differences of at least ten percentage points among comparison groups are highlighted in 
the results. The chi-square test for trend was used to assess the statistical significance of 
observed trends based on state population, recent state funding levels and recent state 
WNV burden (since all categorizations were ordered). Only statistically significant trend 
associations are reported. Data analysis was performed using Microsoft Excel and Epi 
Info
TM




All 50 states and the six ELC-supported LHDs responded, as well as 15 (63%) of the 24 
other surveyed LHDs These 15 LHDs include 13 that met the criterion of having had at 
least 100 cumulative reported cases of WNV neuroinvasive disease and two that had 
local dengue transmission. 
 
Results are presented using figures to highlight important findings. Referenced tables can 





One set of staffing questions pertained to whether states had any staff devoted to WNV 
surveillance with a master’s or higher level degree and if so, their number and funding 
source. The percentage of states with at least one such staff member spending at least 
50% time on WNV decreased substantially from 2004 to 2012 for each of three degree  
 
categories (See Figure 2). More than half of states had someone with a graduate 
epidemiology degree who spent 50% or more of their time on WNV activities in 2004 
versus about 30% of states who had such an employee in 2012. Nearly half had someone 
with a clinical degree—MD/DO, DVM or RN—who spent half time or more on WNV in 
2004 versus not quite 30% in 2012. Overall, there was a 41% decrease in the number of 
staff, including administrative and clerical staff, working at least half time on WNV and 
other mosquito-borne disease surveillance:  from 348 positions in 2004 to 206 positions 
in 2012. These included a 40% decrease in the number of staff with at least master’s 
level-training working 50% or more of their time on WNV, from 168 positions to 100 
positions (See Table S1).  
 
The reductions were smaller for part-time staff-persons spending <50% of their time on 
WNV (See Figure 2, Table S1):  in 2012 there were 297 such staff compared to 354 in 
2004, a 16% drop. Of note, some states have both staff working ≥50% time on WNV 
surveillance and staff working <50% time on WNV surveillance. 
 
Although all state WNV programs are supported in part by CDC funding, 36 (72%) have 
invested state funds as well. In fact, the aggregate state investment in WNV and other 
mosquito-borne disease surveillance exceeds the CDC investment. Overall, 60% of staff, 
including contract staff, working ≥50% time on WNV (124.3/206 staff) are not federally 
supported (See Table S3). This tally includes 70% of those with graduate degrees 
working ≥50% time on WNV (69.5/100) (See Figure 2a, Table S3). In contrast, most 
staff (56%) working <50% time on WNV are supported by CDC funds (166/297), 
including most (55%) of such staff with graduate degrees (75/136) (See Table S3).  In 
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toto, CDC funding supports more than twice the number of <0.5 full time equivalent 
(FTE) positions (166) as 0.5-1.0 FTE positions (81.7). 
 
Staffing was also assessed in a different 
way: number of FTEs, not individual staff, 
by functional category. In 2012, there were 
208.9 state FTE positions dedicated to 
WNV (See Table S4). Of these, 17% were 
held by epidemiologists, 31% by laboratory 
staff, 27% by mosquito/environmental 
surveillance staff, and 25% by other 
surveillance/clerical/administrative staff 
(See Figure 3, Table S4).  
 
The number of FTEs per state in each 
functional category was associated with several state characteristics. The average number 
of FTE epidemiologists working on WNV per state increased with increasing 2012 ELC 
funding level (See Figure 4a). The average number of FTE laboratory staff working on 
WNV per state increased with increasing 2012 ELC funding level and with increasing 
state population (See Figure 4b).  Neither of the other job categories staff numbers was 
associated with funding level or population size. 
 
If funding were available, many states would expand their WNV surveillance staff in 
order to achieve full surveillance capacity (See text box for definition of full 
epidemiology and laboratory capacity). Overall, 13 states reported needing additional 
staff in all four functional job categories, and 40 reported needing additional staff in at 
least one category. Specifically, 27 states (54%) reported needing more epidemiologists, 
30 (60%) reported needing more laboratory staff, 28 (56%) reported needing more 
mosquito/environmental surveillance staff, and 19 (38%) reported needing more 






States reporting additional staffing needs had, on average, fewer workers in each 
functional job category than states reporting no additional staffing needs:  0.67 FTE 
epidemiologists versus 0.75, 0.99 FTE laboratorians versus 1.83, 0.73 FTE 
mosquito/environmental surveillance staff versus 1.76 and 0.43 FTE “other” staff versus 
1.48 (See Figure 6, Table S4).  
 
Altogether, state respondents reported needing 122.6 additional FTE staff, especially   
mosquito/environmental surveillance staff, who, at 53.6 FTEs, comprised 44% of the 
total reported staffing shortfall (See Figure 7, Table S4).  
 
Among the states with reported staffing 
deficits, those with larger populations, 
more WNV cases in the preceding five 
years and more WNV ELC funding in 2012 
indicated the greatest need for additional 
epidemiology staff:  1.4 FTEs per state for 
states with population >7 million versus 0.8 
for the others, 1.3 FTEs per state with the 
Full epidemiology and laboratory capacity to conduce WNV and other mosquito-
borne disease surveillance: 
1) ability to complete a standard case report form on every suspected/confirmed 
mosquito-borne arboviral disease case and report it to ArboNet;  
2) ability to test by IgM for all relevant arboviruses (including dengue) on any 
CSF or serum specimen submitted to the state or city/county laboratory on a 
suspected case of arboviral disease; and 
3) have an environmental surveillance system that includes mosquito surveillance 
to routinely monitor both larval and adult arboviral activity in all parts of your 
jurisdiction in which there is the potential for human outbreaks of arboviral 
disease based on past experience. 
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highest number of WNV cases in 2008-2012 versus 0.8 for the others, and 1.5 FTEs per 
state with >$300,000 in WNV ELC funding in 2012 versus 0.9 for those with less. The 
same trends held for reported mosquito/environmental surveillance staffing needs:  2.8 
FTEs per state for states with  population >7 million versus 1.6 for the others, 3.3 FTEs 
per state with the highest number of WNV cases in 2008-2012 versus 1.6 for the others, 
and 3.1 FTEs per state with >$300,000 in WNV ELC funding in 2012 versus. 1.8 for 
those with less.  
 
For laboratorians, the reported need was greater in more populous states:  1.3 FTEs for 
states with >7 million residents, 1.0 FTE for states with 4.5-6.9 million residents, 0.7 
FTE for states with 1.8-4.4 million residents, and 0.6 FTE for those with less than 1.8 
million residents. Similarly, a greater proportion of high-population states reported a need 
for other/clerical/administrative staff than did less populous states. Just 17% of the 
smallest states (by population size) reported a need for additional 
other/clerical/administrative staff, compared with 31% of small-medium sized states, 
46% of medium sized states and 58% of the most populous states (>7 million) (p<0.05). 
 
Overall, a 59% increase in staffing is needed 
to achieve full epidemiology and laboratory 
capacity among states for WNV and other 
arboviral surveillance. By job category, this 
includes a 72.5% increase in 
epidemiologists, a 40.9% increase in 
laboratory staff, a 93.7% increase in 
mosquito/environmental surveillance staff, 
and a 33.3% increase in “other” staff (See 
Figure 8).   
 
The need for additional staff was not 
associated with whether a state had state-
funded positions; 86% of states without a 
state-funded position needed additional staff 
versus 75% of states with state-funded 
positions. However, the five states with the 
least ELC WNV funding in 2012 all 
reported a need for additional epidemiology, 
laboratory and mosquito/environmental 
surveillance staff. Further, the percentage of 
states needing additional laboratorians 
increased in inverse proportion to 2012 ELC 
funding levels:  38% of those with 
>$300,000 reported a need for additional laboratorians, 56% of those with $200,000-
$299,000, 62% of those with $100,000-$199,000, and 100% of those with <$100,000 
(p=0.04) (See Figure 9).  
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Staffing needs are greatest in the Southeast 
and South-Central US Public Health Service 
regions, where 69% of states reported 
needing more epidemiologists, 77% reported 
needing more laboratorians and 77% 
reported needing more 
mosquito/environmental surveillance staff 
(See Figure 10). In contrast, staffing needs 
are least severe—although still substantial—
in the West/Northwest and Rocky Mountain 
US Public Health Service regions, where 
29% of states reported needing more 
epidemiologists, 43% reported needing more laboratorians and 29% reported needing 
more mosquito/environmental surveillance staff.  
 
The proportion of states with adequate access 
to medical entomologists within or outside 
the public health agency and to expertise in 
wildlife biology within the agency fell 
roughly 10 percent from 2004 to 2012 (See 
Figure 11, Table S5). 
 
Overall Surveillance for WNV 
There were three changes of note in overall 
surveillance efforts for WNV from 2004 to 
2012:  (a) the percentage of responding states 
with an avian mortality system plummeted 
from 98% to 39%, (b) the percentage with 
state-level mosquito surveillance dropped 
from 96% to 80% (See Figure 12), and (c) 
percentages of responding states with active 
human, equine or avian mortality 
surveillance dropped sharply (See Table S6). 
In 2012, just four responding states 
conducted active surveillance for equine 
WNV (down from 23 in 2004) and four for 
avian WNV mortality (down from 42 in 
2004).  
 
Access to a medical entomologist within the agency and to a state public health 
veterinarian were both strongly associated with larger state population. More than half 
(58%) of states with >7 million residents had a medical entomologist within the health 
agency, compared with 8% of those with <1.8 million residents. And all of the most 
populous states had a state public health veterinarian, compared with 50% of the least 
populous states (p<0.002, chi square for trend for each).  
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Human Surveillance  
Human WNV surveillance occurs in all 
states, but became less intense and less 
rigorous in many states between 2004 
and 2012. Fewer states actively 
contacted providers most likely to see 
WNV patients (neurologists, critical care 
specialists and infectious disease 
specialists) to encourage reporting, and 
fewer states required confirmation of 
commercial laboratory-positive 
specimens (See Figure 13). 
  
However, by 2012, all states required 
WNV reporting by in-state laboratories, most states still actively contacted key providers 
to encourage reporting, and elapsed time from specimen collection to case reporting to 
the WNV surveillance program or to ArboNET was unchanged. 
 
Although 2013 WNV surveillance guidance recommends that states audit in-state 
laboratories and review hospital discharge data to assure completeness of WNV case 
reporting, few states did either in 2012.  
 
States reporting a need for additional 
epidemiologists (n=27) were less likely than 
those reporting adequate epidemiology staff 
(n=19) to have conducted outreach to 
encourage medical specialists to report 
positive WNV cases, including contacted 
neurologists (46% vs. 67%), contacted critical 
care specialists (46% vs 61%), contacted 
infectious disease specialists (54% vs 72%), 
and contacted emergency departments (56% 
vs 72%). (See Figure 14). States with 
insufficient epidemiology staff were also less 
likely to have performed end of the year 
catch-up surveillance, by contacting hospital or commercial laboratories (0% vs. 16%). 
However, there was no striking difference in the reporting time for positive human WNV 
cases or in the interval of time taken to report positive cases to ArboNet.  
 
Equine Surveillance  
Although equine WNV surveillance was pursued less intensely in 2012 than in 2004, 
most states in 2012 had systems in place for notification of possible equine cases (88%); 
had arrangements to test equine specimens for WNV (84%), other arboviruses (66%) and 
rabies (89%); and investigated reported clusters of equine illness to determine the cause 
of illness (50% of those with reported clusters) (See Table S8a).  
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Avian Surveillance  
Only 12 US states (24% of respondents) maintained a database of dead bird sightings in 
2012 compared with 57% in 2004. Of those 12, almost all tested some of the dead birds 
for WNV, but only three states tested all dead birds (See Table S8b).  
 
Mosquito Surveillance  
Although mosquito surveillance has become an essential element of WNV surveillance, 
capacity for such surveillance decreased somewhat between 2004 and 2012 (See Figure 
15, Table S9). As noted above, fewer states conducted state-level mosquito surveillance 
in 2012 than did so in 2004 (80% vs. 94%). In addition, states reported that fewer LHDs 
conducted adult and larval mosquito surveillance. In 2004, 48% of states reported that 
“most LHDs in the state” conducted adult mosquito surveillance and 30% reported that 
“most LHDs in the state” conducted larval surveillance; in 2012 those percentages fell to 
34% and 18%, respectively. Further, the median percentage of the population covered by 
mosquito surveillance in states dropped from 65% to 50%, and the median number of 
mosquito trap-nights dropped from >2600 to 1071 (See Table S9).  Finally, among 40 
responding state-funded laboratories doing 
mosquito testing, 68% (27) have cut back on 
testing mosquito pools for WNV. Most (22) 
test fewer pools, and several no longer test 
any (3) (See Table S10). 
 
Nonetheless, most states still conduct some 
mosquito surveillance, identify mosquitoes to 
species (86%) and do some testing for WNV 
(84%), with more than half testing for at least 
one other arbovirus. However, fewer than 
half of states (41%) calculate or receive data 
on minimal mosquito WNV infection rates.  
 
States reporting a need for additional 
mosquito/environmental surveillance staff 
reported fewer mosquito trap-nights than 
states with sufficient staff (median 1,007 vs. 
1,589), were more likely to report a 
decreased number of trap sites in response to 
funding cuts (75% vs. 43%, p=0.04), were 
less likely to have ever performed 
adulticiding (77% vs. 92%), and were less 
likely to have found Aedes aegypti in their 
state (31% vs. 50%) (See Figure 16). Those 
with mosquito/environmental surveillance 
staffing needs also had less laboratory 
capacity for mosquito testing, were less likely to test mosquito pools (75% vs. 86%), 
were more likely to report diminished testing capacity since 2008 (73% vs. 64%), and 
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were more likely to have decreased the number of mosquito pools tested in response to 
ELC funding cuts (75% vs. 64%).  However, they were just as likely to conduct state-
level mosquito surveillance, to collect information from local jurisdictions and to identify 
mosquitoes to species. 
 
Funding and population size were each associated with key mosquito surveillance 
activities. States with comparatively greater 2012 funding were more likely to collect 
information about mosquito surveillance from local jurisdictions (100% for states with 
highest funding levels vs. 40% for those with lowest) and to either identify mosquitoes to 
species or receive reports with this information (100% for highest vs. 20% for lowest, 
p<0.01 for each, chi-square for trend over 4 groups). More populous states were more 
likely to perform or to fund mosquito testing for WNV (100% for most populous group 
vs. 50% for least populous) and to have identified Aedes aegypti in the past year (58% in 
most populous states vs. 17% in least populous, p<0.02 for each, chi-square for trend 
over 4 groups).   
 
Prevention  
In general, use of the media and other 
vehicles to educate residents about WNV 
prevention was high in 2012 and roughly 
comparable to prevention efforts documented 
in 2004. There were several exceptions, 
though:  in 2012, fewer states had modified 
messages for lower literacy and non-English 
speaking audiences, had aired public service 
announcements regarding WNV prevention, 
had actively distributed informational 
brochures and had participated in community 
meetings (See Figure 17, Table S11).  
 
Mosquito control activities  
Mosquito control activities were not assessed in 2004.  
 
In 2012, only 58% of responding states 
reported having a plan for WNV control that 
includes adulticiding. Among these states, 
half have a threshold for adulticiding based 
solely on vector mosquito prevalence or 
WNV mosquito infection rate. Overall, 80% 
of responding states have ever conducted 
adulticiding to control WNV (See Figure 18).  
 
The main reported reason for not having 
done adulticiding is insufficient outbreak 
threat. Still, one of the four states that have 
not performed adulticiding reported that it 
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would have done so if funding had been 
available. And seven states reported 
having “insufficient funding to adulticide” 
in 2012, despite an outbreak threat. 
Altogether, 27% of responding states 
reported the existence of an emergency 
funding mechanism to support 
adulticiding for WNV (See Figure 19, 
Table S12).   
 
Larviciding was conducted in three 
quarters of states (78%), mostly by LHDs 
with their own funding. However, 31% of 
states either conducted or financially supported  
larviciding in 2012, and another 25 states might have done so if they had funding. 
 
Regarding other arboviruses, five states reported mosquito adulticiding in 2012 for 
arboviral threats other than WNV:  four for EEE and one for dengue. A total of 18 states 
have identified Aedes aegypti mosquitoes in the past five years.  Five of these have 
written dengue surveillance and control plans (See Table S12).  
 
Overall WNV Laboratory Capability 
Since 2004, the most basic WNV testing 
capability for human specimens, serum 
IgM testing, has been maintained at 
nearly all state public health laboratories, 
and capability for testing mosquitos via 
polymerase chain reaction (PCR) testing, 
culture, VecTest or RAMP has been 
maintained in most states.   
 
However, testing capability has been 
reduced greatly for equine and for avian 
testing and for human PCR testing (See 
Figure 20, Table S13). 
 
Approximately 40% of state laboratories 
in responding states maintain plaque 
reduction neutralization test (PRNT) 
capability to confirm WNV in human 
specimens, the same proportion as in 
2004.  Other states depend on CDC to 
perform confirmatory PRNT testing.   
 
Compared with states reporting adequate 
WNV laboratory staff, states reporting a 
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need for additional laboratorians for WNV surveillance were less likely to perform 
testing on mosquito pools in 2012 (73% vs. 90% of responding states), more likely to 
report a reduction in mosquito pool testing capacity since 2008 (77% vs. 53%), less likely 
to have at least some WNV testing capacity (90% vs. 100%), and less likely to test WNV 
specimens for other mosquito-borne viruses (56% vs. 69%) (See Figure 21).  
 
Testing capability for other mosquito-borne viruses and efforts to detect them  
There is wide variability in state public health laboratory capacity to test WNV 
specimens for other mosquito-borne viruses (See Figure 22, Table S14, Table S15). Next 
to WNV, states are most prepared to test specimens for SLE and EEE. Of the responding 
states, 34 reported capacity to test for SLE and 24 to test for EEE. Over half of 
responding states (56%) routinely test 
cerebrospinal fluid specimens for SLE and 
over a quarter (28%) for EEE. In all, 
respondents reported the testing of more 
than 4,500 specimens for each of these 
arboviruses.   
 
About 40% of responding states have 
capability for WEE and LaCrosse virus 
testing. However, routine testing of 
cerebrospinal fluid specimens for these 
pathogens occurs in few states (14% and 
12% of responding states, respectively). 
 
Just 16 responding states reported testing 
for LaCrosse virus, four for Powassan virus 
and nine for dengue. Although only 328 
dengue tests were reportedly performed in 
state public health laboratories in 2012, 
42% (137) were positive, making it the 
third most commonly detected arbovirus in 
state laboratories, behind WNV (2,795) 
and SLE (167) and ahead of LaCrosse 
virus (120) and Powassan virus (61) (See 
Figure 23). Chickungunya virus and 
Colorado tick fever virus testing capability 
was limited to two laboratories and were 
rarely tested for. Although tested for by a small percentage of state laboratories, when 
testing was done, LaCrosse and Powassan viruses were more likely to be detected than 






Relationship of ELC funding to other surveillance capacities and response to 
reductions in funding  
ELC funding for WNV continues to have 
a beneficial effect on surveillance for 
other mosquito-borne, tick-borne and flea-
borne diseases. Comparable proportions of 
respondents cited a beneficial impact—
especially on mosquito-borne disease 
detection—in 2004 and 2012, despite 
decreases in WNV-specific funding (See 
Figure 24, Table S16). 
 
States were asked how they have managed 
reductions to ELC funding for WNV 
surveillance. Funding cuts prompted 57% 
of responding states to eliminate dead bird 
surveillance, 58% to decrease mosquito 
trapping and 68% to decrease mosquito 
testing. Almost half (46%) have decreased 
the number of human specimens tested for 
WNV (See Figure 25, Table S16).   
 
States with reported laboratory staffing 
needs were somewhat more likely to 
indicate that ELC funding had enhanced 
surveillance for other mosquito-borne 
diseases (100% vs. 87%) and tick-borne 
diseases (65% vs. 53%). States needing 
additional epidemiology or 
mosquito/environmental surveillance staff were less likely than those with adequate staff 
to report that ELC funding had enhanced state capabilities for flea-borne disease 




ELC-SUPPORTED LHDS 2012 VS. 2004 
 
Like state survey respondents, LHD respondents reported capacity to carry out the most 
important WNV functions in 2012—human and mosquito surveillance—but reported 
having fewer federally funded staff to do this work and slightly lower surveillance levels 
than in 2004. While these localities reported having more or less maintained levels of 
human and mosquito surveillance since 2004, their public health laboratory capacity was 
greatly reduced compared to states.  
  
Staffing  
In 2004, the six ELC-supported LHDs reported having a collective total of 21 employees 
and contract staff with at least a master’s degree working ≥50% time on WNV. In 2012, 
they reported having a collective total of 20 such employees, a negligible change (See 
Table ELC1). 
 
All six 2012 LHD respondents have locally as 
well as ELC-supported positions dedicated, at 
least in part, to mosquito-borne virus 
surveillance (See Figure 26). As in states, most 
staff working ≥50% time on WNV (20/29) are 
not funded by CDC, including 60% of those 
with master’s or higher-level degrees (12/20) 
(See Figure 26, Table ELC3). Unlike states, 
however, most staff working <50% time on 
WNV do not receive CDC funding either. 
Overall, 87% of those working <50% time on 
WNV are not supported by CDC funding 
(26/30), including most of such staff with 
master’s or higher-level degrees (10/14) (See Table ELC3).   
Overall, CDC funding to LHD respondents supports  
more >0.5 FTE positions (9) than <0.5 FTE 
positions (4), and almost all CDC-supported 
positions (12/13) are held by individuals with 
master’s level or higher training. 
 
In 2012, responding ELC-supported LHDs 
reported 27.9 FTEs working on WNV and 
other mosquito-borne virus surveillance 
(mean, 4.7 per LHD vs. 4.2 per state health 
department). The distribution of FTEs in 
LHDs was different than in state health 
departments. ELC-supported LHDs have 
relatively more epidemiology and mosquito 
surveillance staff: 25% of FTEs are epidemiologists and 56% mosquito-borne disease 
staff vs.17% and 27%, respectively, in state health departments. They have relatively 
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fewer laboratory and support staff (7% of FTEs are laboratory and 13% support staff vs. 
31% and 25%, respectively) (See Figure 27).  
 
Four (67%) LHDs reported needing more epidemiologists to achieve full epidemiology 
capacity for mosquito-borne virus surveillance. All four of the LHD respondents with 
laboratories reported needing more laboratorians to achieve full laboratory capacity for 
mosquito-borne disease surveillance. Three LHDs reported needing more 
mosquito/environmental surveillance staff, and two reported needing more 
clerical/administrative staff (See Figure 28a, Table ELC4).   
 
 
Altogether, the six respondents cited a need 
for 15 additional FTE positions to achieve 
full epidemiology and laboratory capacity, 
with most being for mosquito/environmental 
surveillance staff (7 FTEs) (See Figure 28b, 
Table ELC4). The relative increase to 
achieve full capacity by functional category 
is a 54% increase in staffing overall, 
including a 43% increase in epidemiologists, 
a 158% increase in laboratory staff, a 45% 
increase in mosquito/environmental 
surveillance staff, and a 57% increase in 
“other” staff (See Figure 29, Table ELC4).  
 
Compared with states, ELC-supported LHDs with full capacity would have more 
epidemiologists per agency (1.65 vs. 1.22), fewer lab staff (1.22 vs. 1.86), more 
mosquito/environmental surveillance staff (3.60 vs. 2.26) and fewer “other” staff (0.92 
vs. 1.43). 
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Overall Surveillance for WNV 
There were three changes of note in overall 
surveillance efforts for WNV from 2004 to 
2012:  (a) the percentage of ELC-funded 
LHDs with an avian mortality system dropped 
from 100% to 67%, (b) the percentage with 
equine disease surveillance dropped from 
50% to 20%, and (c) the percentages with 
active human and equine surveillance both 
dropped sharply (See Figure 30, Table ELC6).   
  
Human Surveillance for WNV 
As among state respondents, responding ELC-
funded LHDs reported conducting human 
WNV surveillance, but doing so less actively 
than in 2004. Slightly fewer LHDs contacted 
neurologists and critical care specialists to 
encourage WNV reporting, but all indicated 
contacting infectious disease specialists and 
emergency departments (See Figure 31, Table 
ELC7).  
  
All LHD respondents also reported continued 
requirements for WNV reporting by in-state 
laboratories in 2012, and the reported average turn-around-time from specimen collection 
to positive case reporting to the WNV surveillance program was the same as in 2004. 
 
No LHD respondent reported auditing laboratories or reviewing hospital discharge data 
in 2012 to assure completeness of WNV case ascertainment.  
 
Equine Surveillance  
There was little equine WNV activity in 2012 and thus limited ability to assess workload 
changes (See Table ELC8a).  Just two LHD respondents reported having a system in 
place for reporting cases of equine neurologic disease to state authorities, and only one 
LHD reported testing any equine specimens for WNV. However, equine surveillance is 
not emphasized in these agencies. 
    
Avian Surveillance 
Compared with 2004, the level of LHD avian surveillance was low:  one LHD terminated 
its avian surveillance program, and only small numbers of dead birds were tested at any 
site (median 25 per site for 3 sites) (See Table ELC8b).  
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Mosquito Surveillance  
As in states, mosquito surveillance capacity 
decreased somewhat in ELC-funded LHDs 
between 2004 and 2012, by some measures 
(See Figure 32). Only two LHDs reported 
conducting larval mosquito surveillance in 
2012, compared with four in 2004. The 
number of mosquito trap-nights dropped 
from a mean of 4,632 in 2004 to 300 in 
2012 (See Table ELC9). Of the four 
responding LHDs that test mosquitoes, one 
tested fewer mosquito pools for WNV in 
2012—a strategy also used by some state 
public health laboratories to compensate 
for funding losses. (Table ELC10).  
Nonetheless, all six LHD respondents conduct mosquito surveillance, and five identify 
mosquitoes to species and calculate minimum mosquito infection rates as part of their 
WNV response plans.  
 
Four LHD respondents have laboratory capacity within the agency for mosquito testing; 
the other two rely on state public health laboratories for mosquito testing. Just one of the 
four LHDs with laboratory capacity reported a drop in capacity to test mosquito pools 
since 2008—a smaller percentage than for state laboratories (68%).  
 
Prevention  
In general, use of the media and other vehicles to educate residents about WNV in 2012 
was high, and unlike in states, comparable to efforts in 2004 (See Table ELC11).  
 
Mosquito control activities  
Mosquito control activities were not 
assessed in 2004.  
 
In 2012, five of the six LHDs had a plan 
for WNV surveillance and control 
(compared with 58% of responding states) 
(See Figure 33). Four of these LHD plans 
do not require human cases before 
adulticiding is recommended, compared to 
only half of states. Three LHD respondents 
reported conducting larviciding in 2012. 
However, as in states, more jurisdictions 
would have performed larviciding, or would  
have expanded its larviciding, if funding had been available (See Table ELC12).   
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All but one of the responding LHDs have 
conducted adulticiding at some point in time 
to control WNV. The sole responding LHD 
that has not conducted adulticiding relies on 
another jurisdiction to provide this service. 
Although no responding LHD performed 
adulticiding for viruses other than WNV in 
2012, the one jurisdiction with an outbreak 
threat might have done so if funding had 
been available. Two responding LHDs have 
an emergency fund or funding mechanism 
to support adulticiding for WNV (See 
Figure 34).   
 
Although three responding LHDs have identified Aedes aegypti mosquitoes in the past 
five years, none has written dengue surveillance and control plans, compared with 28% 
of states that have identified Aedes aegypti in the past five year.   
 
Overall WNV Laboratory Capability  
Since 2004, there has been a large 
reduction in LHD laboratory capabilities 
(See Figure 35, Table EC13). Among the 
six LHDs, the number of LHD laboratories 
doing any testing for WNV fell from six to 
four. The number of laboratories 
performing human IgM testing fell from six 
to two. No LHD respondents reported any 
testing of equine or avian samples in 2012, 
compared with two and three, respectively, 
in 2004. The number of LHDs reporting 
mosquito testing dropped from three to one.  
 
Two LHD respondents reported that their laboratories maintain PRNT capability, 
representing no change from 2004. Three other respondents rely on either another state’s 
public health laboratory or CDC to do confirmatory PRNT testing.   
 
Testing capability for other mosquito-borne viruses and efforts to detect them 
Testing capability and efforts to detect other mosquito-borne viruses on specimens 
submitted for WNV testing are more limited in ELC-funded LHD laboratories than in 
state public health laboratories (See Table ELC14, Table ELC15). Among the four LHD 
respondents with agency laboratories, just one routinely tests cerebrospinal fluid 
specimens for mosquito-borne viruses other than WNV—and it tests only for SLE. The 
only other mosquito-borne viruses responding LHDs tested for in 2012 are dengue (by 
one LHD laboratory), SLE (by two LHD laboratories) and WEE (by one LHD 
laboratory).  
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Relationship of ELC funding to other surveillance capacities and response to 
reductions in funding  
ELC funding for WNV surveillance 
continues to benefit LHD surveillance 
programs for other mosquito-borne, tick-
borne and flea-borne diseases (See Figure 
36, Table ELC16). The percentages of 
responding LHDs that cited a beneficial 
impact on each since 2004 increased, 
despite decreases in WNV-specific 
funding. 
 
Respondents cited a variety of strategies to 
manage ELC funding cuts for WNV and 
other mosquito-borne disease surveillance 
in addition to eliminating laboratory 
services:  eliminating dead bird 
surveillance (2 LHDs), curbing mosquito 
trapping (3 LHDs), reducing mosquito 
pool testing (1 LHD) and reducing human 
WNV testing (1 LHD) (See Figure 37, 







NON-ELC-SUPPORTED VS ELC-SUPPORTED LHDS, 2012 
 
Compared with ELC-funded LHD respondents, the 15 non-ELC-funded LHD 
respondents reported less direct capacity for WNV surveillance in 2012, especially 
laboratory capacity, and relied more heavily on state services. However, many had 
substantial capacity for mosquito surveillance. 
  
Overall Surveillance and Staffing  
Both ELC-funded and non-ELC-funded LHDs reported that most of their mosquito-borne 
disease surveillance staff are not funded by CDC. About two-thirds of all professional 
staff who spend any amount of time on mosquito-borne disease surveillance in 
responding LHDs receive funding from non-CDC sources. Most CDC funding for 
responding LHDs—whether ELC-supported or not—supports staff members who spend 




Compared with their ELC-supported 
counterparts, non-ELC-supported LHDs 
were less likely to conduct any type of WNV 
surveillance:  human, mosquito, equine or 
avian (See Figure 38, Table LHD6). No LHD 
not receiving ELC funds conducted its own 
human WNV surveillance, but two-thirds 
(10/15) conducted their own mosquito 
surveillance.  
 
Overall, the 15 non-ELC-funded LHD 
respondents had 141 FTE staff members 
involved in some aspect of mosquito-borne 
viral disease surveillance. Staffing patterns were similar to those reported by the six 
responding ELC-supported LHDs:  56% perform mosquito surveillance, 22% “other” 





The non-ELC-funded LHDs conducting at least some mosquito-born virus surveillance 
averaged more FTE positions devoted to those activities than the six responding ELC-
supported LHDs:  9.4 versus 4.7 FTEs per LHD overall. Moreover, the trend held for 
each of four functional job categories: an average 1.7 versus 1.2 epidemiology FTEs, 1.8 
versus 0.5 laboratory FTEs (comparing those respondents with agency laboratories), 7.8 
versus 2.6 mosquito/environmental surveillance FTEs (comparing those respondents with 
mosquito surveillance programs), and 2.1 vs. 0.6 “other” FTEs (See Figure 40, Table 
LHD4).   
 
Only 27% of non-ELC-supported LHDs 
reported a need for additional epidemiology 
staff, compared with.67% of ELC-supported 
LHDs. But, 80% of the ten non-ELC-
supported LHDs with mosquito surveillance 
programs reported a need for more mosquito 
surveillance staff, compared with half (50%) 
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of the ELC-recipients (See Figure 41, Table LHD 4). In agencies with reported staffing 
needs, the average FTE need was higher in non-ELC-supported LHDs than in ELC-
supported LHDs for laboratory staff (1.1 vs. 0.8 FTE), mosquito/environmental 
surveillance staff (3.7 vs. 2.3 FTEs) and “other” support staff (2.3 vs. 1.0) (See Figure 42, 
Table LHD4). 
 
Overall, mosquito/environmental surveillance staff accounted for the biggest share of 
additional need in both types of LHDs:  47% of needed staff in ELC-supported LHDs and 
60% of needed staff in non-ELC-supported LHDs. The total additional need was 15 FTEs 
in the six ELC-supported LHDs and 49.2 FTEs in the 15 non-ELC-funded LHDs. To 
achieve full capacity for WNV and other mosquito-borne viral disease surveillance, the 
15 non-ELC-funded LHDs reported needing a total of 180.2 FTEs, overall, including 
current and additional needed staff (See Figure 43, Table LHD4). 
 
Compared with the ELC recipients, the non-ELC LHDs had lesser access to expertise in 
medical entomology (29% vs. 50%), wildlife biology (20% vs. 50%) and veterinary 
medicine (33% vs. 50%) within their agency.  
  
Human Surveillance for WNV 
Despite not conducting their own 
surveillance for human WNV, many non-
ELC-funded LHDs reported contacting key 
providers to encourage WNV reporting: 
neurologists (33%), critical care specialists 
(47%), infectious disease specialists (47%) 
and emergency departments (53%). 
However, these percentages are generally 
half those of ELC-supported LHDs (Figure 
44, Table LHD7). 
 
In 2012, one responding non-ELC-funded 
LHD audited laboratories and reviewed hospital discharge data to assure completeness of 
WNV case ascertainment within its jurisdiction, something no ELC-funded LHD did. 
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Equine Surveillance  
Although nearly a third of all responding LHDs reported having a system in place for 
reporting cases of equine neurologic disease to the state health agency, just one (non-
ELC-supported) LHD was informed of clusters of equine illness within the jurisdiction in 
2012 and participated in the ensuing investigation (See Table LHD8a). 
    
Avian Surveillance 
Two non-ELC-funded LHDs (13%) and three ELC-funded LHDs (50%) reported 
maintaining a database of dead bird sightings in 2012. All five of these agencies 
submitted dead birds for testing in 2012, mostly to the state laboratory (60%). The 
median quantity submitted was 16-25 birds (See Table LHD8b).    
 
Mosquito Surveillance  
While all responding ELC-supported LHDs perform their own mosquito surveillance, 
just two thirds (67%) of non-ELC-supported LHDs reported doing so. However, those 
non-ELC-recipients conducting mosquito surveillance generally conduct as many or 
more types of mosquito surveillance activities than their ELC-funded counterparts:  larval 
surveillance (90% vs. 67%), mapping larval breeding sites (57% vs. 50%), identifying 
mosquitoes to species (90% vs. 100%), trapping at fixed sites (90% vs. 100%), 
surveilling 100% of the local population (median, 100% each), and having mosquitoes 
tested for arboviruses other than WNV (See Tables LHD 9, 10).   
 
Prevention  
In general, use of the media and other vehicles to educate residents about WNV in 2012 
was high for both types of LHDs. However, the percentages of responding agencies 
performing specific outreach activities—such as airing public service announcements, 
hosting community meetings or conducting door-to-door outreach—were 5-25% lower 
among LHDs without ELC funding (See Table LHD11).   
 
Mosquito control activities  
Both types of LHDs reported active roles in mosquito control. Of note, the non-ELC-
funded LHDs tended to be more active in larval control while the ELC-funded agencies 
were more active in adult mosquito control.  
 
Non-ELC-funded LHDs were more 
likely to have ever financially supported 
larviciding (100% vs. 80%) and to have 
conducted/supported it in 2012 (92% vs. 
60%). They were also less likely to have 
had insufficient funding to conduct 
larviciding (13% vs. 60%) (See Figure 
45, Table LHD 12). 
 
ELC-supported LHDs were more likely 
to have a WNV control plan that includes 
adulticiding (100% vs. 71%), to have 
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ever conducted adulticiding for WNV control (83% vs. 64%) and to have an emergency 
funding mechanism for adult mosquito control (40% vs. 29%). ELC-funded LHDs were 
less likely to have ever had a threat that reached the adulticiding threshold but for which 
there was no funding (0% vs. 17%) (See Figure 46, Table LHD 12). 
 
 
While 40% or more of both groups reported 
a documented Aedes aegypti presence, only 
non-ELC-funded agencies had a written 
dengue surveillance and control plan (2 of 5 









Relationship of ELC funding to other surveillance capacities and response to 
reductions in funding  
While ELC funding has clearly enhanced surveillance capacity for related vector-borne 
diseases in LHDs with direct ELC support, ELC funding has also impacted, to a lesser 
extent, non-ELC-supported LHDs (See Figure 47, Table LHD16). 
 
 
Anywhere from one quarter to three quarters of responding LHDs—ELC-funded and 
not—report that ELC funding cuts have prompted the elimination or reduction of dead 
bird surveillance, reductions in mosquito trap sites and reductions in the number of 







Prior to the introduction of WNV in the US, there was neither federal funding nor a real 
national system for arboviral surveillance. The introduction of WNV led to the formation 
of ArboNet, now a distributed national system with participation from every state and six 
independently-funded LHDs, coordinated by CDC. ArboNet is now a critical part of the 
infrastructure to respond to the introduction/emergence of other arboviral diseases, such 
as dengue, and a platform for monitoring those that are endemic. Yet ArboNET’s 
integrity is only as strong as arboviral disease surveillance systems in state and local 
health departments. 
 
This assessment was conducted for two key reasons:  (a) to examine changes since 2004 
in state and federally-supported LHD capacity to conduct surveillance for WNV and 
other mosquito-borne viruses in light of substantial federal funding cuts and (b) to gauge 
current capacity for WNV and other mosquito-borne virus surveillance in state and local 
health agencies, including LHDs with high historical levels of WNV morbidity, but no 
direct ELC support. In addition, the assessment provided an opportunity to examine other 
funding for surveillance activities, to identify surveillance gaps and to document agency 
needs. Important findings are presented below. 
 
State and local health departments supported with ELC funding  
 Overall state and local capacity for WNV and other mosquito-borne virus 
surveillance has diminished since 2004. There is a 41% reduction in staff working at 
least half-time on WNV-related activities in states. Entomology and wildlife expertise 
is less readily available in health agencies. The percentage of states conducting 
mosquito surveillance and tracking avian mortality fell from 96% to 80% and from 
98% to 39%, respectively. And the intensity of human and mosquito surveillance 
efforts and associated laboratory support has declined significantly; 58% of states 
have reduced mosquito trapping and 68% have reduced mosquito testing. Much of 
this program erosion may be attributable to federal funding cuts. 
 Although almost all states and the six ELC-supported LHDs retain capacity for the 
most basic surveillance for human illness and mosquito disease vectors, some 
agencies are at a critical tipping point. Mosquito surveillance has been compromised, 
critical laboratory capacity has been lost, and efforts to conduct surveillance for other 
arboviruses are patchy, with <25% of states systematically examining submitted 
cerebrospinal fluid specimens for anything other than SLE and EEE. The number of 
states conducting active surveillance for human disease has decreased, many states 
have ceased avian mortality surveillance, and most states are only passively involved 
in equine surveillance. 
 Most state and local health departments have made their own substantial investments 
in surveillance and prevention programs for WNV and other mosquito-borne viruses. 
Nearly 75% of states and all of the six ELC-supported LHDs have staff supported by 
other funding sources working on mosquito-borne virus surveillance.  
 States are an important source of laboratory support for arbovirus surveillance. While 
all states have some WNV testing capacity, just 67% of ELC-supported LHDs and 
only two of 15 non-ELC-funded LHDs have any WNV testing capability. Testing 
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capability for other arboviruses is almost exclusively located at state health 
departments; only two responding ELC-supported LHDs and none of the non-ELC-
supported LHDs have any such capability.  
 ELC funding was instrumental in building the US arbovirus surveillance system and 
remains critical to maintain capacity for arbovirus surveillance in most state and local 
health departments. ELC funding cuts have had an adverse impact, resulting in 
reduced mosquito surveillance (either trapping, testing or both) in approximately 70% 
of states and 75% of LHDs, elimination of avian mortality surveillance in most 
jurisdictions and reduction in the number of human specimens tested for WNV or 
other mosquito-borne viruses. Moreover, states with the biggest need for additional 
laboratory staff are those with the least ELC funding.  
 Approximately 123 FTE positions are needed in 27 state health departments and 15 
FTE positions in four of the six responding ELC-supported LHDs to meet outstanding 
staffing needs for arbovirus surveillance. Based on an average cost of 
$100,000/position (including benefits and indirect costs), the staff funding shortfall 
totals about $13.8 million in these agencies—about the same amount of ELC 
cooperative agreement funding for WNV response that has been lost since fiscal year 
2003-04. (The ELC WNV budget totaled $23.7 million in 2003-04, compared to $9.3 
million at present).  
 There are important gaps in each functional area for arbovirus surveillance that would 
benefit from restoring some of the funding that has been lost. Additional 
epidemiologists are needed to enhance human WNV surveillance and assure efforts 
are made to accurately diagnose other arboviral diseases. Data suggest the potential 
for missing cases of other arboviruses is large when testing is limited to WNV, SLE 
and EEE. Yet, less than a quarter of health departments appear to assure that human 
specimens submitted for WNV testing are also routinely tested for arboviruses other 
than SLE and EEE. Additional laboratory capacity is needed to meet the demand for 
arboviral testing of mosquito pools and for testing human specimens from persons 
with meningitis, encephalitis or syndromes consistent with dengue for other 
arboviruses. In 2012, only 14 (28%) state health department laboratories performed 
testing for arboviruses other than WNV, SLE and EEE, despite having capability. 
Additional mosquito/environmental surveillance staff are needed to conduct annual, 
systematic mosquito surveillance in areas at greatest risk for large outbreaks of 
mosquito-borne viruses, including dengue as well as WNV, SLE and EEE. Reported 
shortfalls of staff for mosquito surveillance, which is labor intensive, were greater 
than for other surveillance activities:  44% of all FTEs reportedly needed by states 
and 47% of those needed by the six responding ELC-funded LHDs are for mosquito 
surveillance.   
 There are gaps in planning, especially at the state level. Despite the presence of WNV 
in all contiguous 48 states since 2004, 42% of states did not have a WNV control plan 
in 2012.  
 The possibility of local dengue transmission with large outbreaks of illness is real.  
Eighteen states have confirmed the presence of Aedes aegypti. Almost all states have 
had at least one imported case of dengue fever and at least two states, Florida and 
Texas, have documented local transmission in several counties.
11,12
 However, only 
five states have dengue surveillance and control plans.  
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 Surveillance data are actively used for prevention activities. In 2012, nearly all states 
notified the public of the threat of WNV by posting information on government web 
pages, among other things. And while prevention activities other than public 
education are not usually supported with ELC funding for surveillance and laboratory 
capacity, most states have jurisdictions that actively larvicide to slow WNV 
amplification and have performed adulticiding when they felt the data warranted it. 
Funding cuts have adversely impacted prevention activities. Compared with 2004, 
fewer states in 2012 actively distributed informational brochures, assured prevention 
messages were tailored for low-literacy groups and non-English speakers, aired 
public service announcements or held town meetings. Overall, more than half of 
states reported that, with sufficient funds, they might have supported larviciding 
efforts by LHDs. 
 
Local-level health departments without direct ELC-support 
 Local health departments with a proven high WNV threat make a major contribution 
to surveillance for WNV and other mosquito-borne viruses, particularly by 
contributing to mosquito surveillance and supporting state-level human disease 
surveillance. The 15 responding non-ELC-supported LHDs contributed an average of 
1.7 FTE epidemiologists, 5.2 FTE mosquito/environmental surveillance staff and 2.1 
FTE “other” surveillance staff to national capacity, compared with an average of 0.7 
FTE epidemiologists, 1.2 FTE mosquito/environmental surveillance staff and 1.1 FTE 
“other” surveillance staff at the state level. Most of these staff are not supported 
through ELC or Public Health Preparedness and Response passdown funding from 
the state.   
 Despite having substantial locally-funded capacity, state-level surveillance capacity 
and support through ELC passdowns are necessary for these LHDs to have 
surveillance data to respond to WNV and other mosquito-borne viruses. Only two of 
15 non-ELC-funded LHDs have their own laboratory, and these two laboratories have 
limited capability to test for WNV and no capability to test for other arboviruses.  
Five responding LHDs without direct ELC support (33%) do not conduct their own 
mosquito surveillance.  Of the ten that do, several reduced the number of mosquito 
pools collected and tested in 2012 as a result of reduced ELC funding. All depended 
on the state for human disease surveillance. In addition, approximately 18 (37%) of 
the 49 staff who spend ≥50% time on mosquito-borne virus surveillance activities are 
supported by CDC funding.  
 LHDs without direct ELC support, but with a proven high WNV threat, need 
additional mosquito and human surveillance staff. There is a particular shortfall of 
mosquito/environmental surveillance personnel. Of the ten LHDs conducting 
mosquito surveillance, eight reported needing a total of 29 additional FTEs for 
mosquito surveillance. 
 LHDs with a proven high WNV threat have taken an active role in mosquito control. 
Almost all conducted larviciding in 2012 and few reported insufficient funding to do 
it.  
 
Given that just over half of all states reported additional staffing needs, it was possible to 
examine whether staffing needs were associated with diminished capacity for arbovirus 
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surveillance. In general they were. States with a reported need for epidemiologists were 
less proactive in contacting providers to encourage arbovirus diagnosis and reporting; 
they also were less likely to test suspect WNV specimens for other arboviruses. States 
with a reported need for laboratory staff were less likely to have capacity to test mosquito 
pools for WNV and more likely to report that testing capacity had fallen since 2008. 
States with a reported need for mosquito surveillance staff were more likely to report 
having decreased the number of mosquito trap-nights and were less likely to have 
identified Aedes aegypti within their geographic area.  
 
Comparisons among state groupings showed few systematic differences.  However, those 
differences identified aid the interpretation of the major findings outlined above. Current 
levels of WNV funding were directly associated with the number of FTE laboratory staff 
and epidemiologists per state. Conversely, the percentage of states needing additional 
laboratorians was strongly inversely associated with current levels of WNV funding. By 
region, southeastern and south central states had the most unmet needs overall, with more 
than 70% of these respondents reporting a need for staff in all four functional categories: 
epidemiology, environmental surveillance, laboratory support and “other.” In contrast, 
relatively few western and Rocky Mountain states reported unmet staffing needs. In most 
regions, the need for additional laboratorians was slightly higher than the need for other 
kinds of staff.  
 
Interpreting the changes in surveillance between 2004 and 2012 needs to be done with 
caution. Since 2004, states and localities have gained more experience with arbovirus 
surveillance, the relative importance of certain surveillance functions has changed, and 
funding cuts have forced some jurisdictions to focus on the most essential components of 
surveillance (human and mosquito). In particular, the importance of avian surveillance 
has diminished for several reasons. Jurisdictions found it difficult to maintain a consistent 
level of public vigilance and reporting from year to year as the public became more 
accustomed to the presence of WNV. There was concern that selective pressure would 
produce a population of Corvidae species (especially crows and blue jays) more tolerant 
of infection, and there was the gradual realization that mosquito surveillance could not 
only replace avian surveillance to detect the presence of WNV but that it could provide 
data of more immediate relevance to human risk and control. The value of equine WNV 
surveillance as an index of human risk also diminished; a result of the licensing and 
widespread use of the WNV equine vaccine and recognition that illness in horses usually 
occurs contemporaneously or later than human illness. From a laboratory perspective, 
reliable commercial laboratory testing of human specimens for WNV became widely 
available, making it less necessary for state laboratories to do high-volume WNV testing.  
 
On the other hand, with diminished avian mortality surveillance, many states were 
compelled to expand mosquito surveillance to cover broader geographic areas.  In 
addition, the recognition of risk posed by other arboviruses has increased. Powassan virus 
encephalitis is a new threat, and its magnitude and trends are poorly understood.
13,14
 
LaCrosse virus has been found to be more widespread than previously recognized. 
Chikungunya virus has the potential to be repeatedly imported, become established and 
cause large outbreaks.
15 
 And dengue has been repeatedly introduced all over the country, 
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with local transmission documented in an increasing number of Florida counties over the 
past four years.
11, 12
 Surveillance systems for mosquito-borne and other arboviruses need 
to have sufficient capacity to rapidly recognize and respond to these challenges.  
   
This assessment has several strengths. The high response rate from ELC-funded 
jurisdictions enables a nationwide assessment of arbovirus surveillance capacity and the 
impact of federal funding. Questions comparing 2004 to 2012 used identical wording, 
maximizing the potential to compare results. Information on the type of funding used to 
support surveillance staff, highlighted the importance of local as well as federal funding 
investments. In addition to current staffing levels, data were obtained on additional 
staffing needs and the nature of them. Many assessments of epidemiology capacity focus 
on states only and thus miss the surveillance and prevention contribution from LHDs and 
their potential need for state and federal support. This assessment extended to LHDs with 
reason to build their own WNV surveillance capacity:  large WNV outbreaks and/or 
consistently significant morbidity in the past, but no direct ELC funding. Finally, the 
assessment obtained information on selected control activities and on dengue risk and 
preparedness.  
 
This assessment also has a number of limitations. First, not all jurisdictions answered all 
questions; estimates of current staffing and staffing needs in particular may be 
underestimated because of incomplete responses. The ambiguity resulting from 
unanswered questions was managed in several ways. For questions about surveillance 
activities, denominators excluded those who failed to answer specific questions, so non-
respondents were not included in the analysis. For questions relating to staffing, non-
responses were treated as “zeros,” i.e., no staff or staff needs.  
 
Second, some respondents may have misinterpreted some questions, particularly those 
related to numbers of staff and FTEs. Misinterpretation could result in over or under-
reporting of FTEs.   
 
Third, some new questions were added to the 2012 questionnaire, particularly relating to 
number of FTEs by functional category and funding sources. Thus, we do not know what 
the state personnel investment was in WNV and other mosquito-borne virus surveillance 
in 2004, and we do not know how that has changed.  
 
Fourth, as previously discussed, the relative importance of different surveillance methods 
shifted between 2004 and 2012. Whereas needs for human surveillance and laboratory 
testing capability and capacity are largely unchanged, the need for avian mortality and 
equine surveillance data has diminished, and the need for mosquito surveillance data has 
increased. Jurisdictions have adjusted resources to accommodate these changes, and this 
accommodation may explain, at least in part, the generally high US WNV surveillance 
capacity, despite federal funding cuts of more than 50%.   
 
Fifth, yearly measures of workload are difficult to compare, as they depend, in part, on 
levels of WNV activity. However, the human WNV burden in 2012 was higher than in 
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2004, as measured by reported cases of neuroinvasive disease (2,873 cases in 2012 vs. 




Finally, the 2012 assessment did not solicit information on funding or unmet needs for 
anything other than staff. Limited fiscal resources may, for example, preclude the 
purchase of updated laboratory equipment and testing reagents, thereby limiting 
laboratory testing of mosquito pools, and testing of human and non-human specimens for 
arboviruses other than WNV. It is likely that unmet non-personnel needs have 
contributed significantly to loss of arboviral surveillance capacity and would need to be 




Based on assessment results, several summary conclusions can be drawn: 
1. All 48 contiguous states retain some capacity for WNV surveillance.   
2. Surveillance capacity varies widely among the states, from a minimal ability to 
diagnose and report WNV human cases to ability for more comprehensive 
surveillance, including monitoring WNV activity in mosquitoes, dead birds and 
sentinel chickens. 
3. Overall, however, state capacity has decreased since 2004, despite WNV 
becoming endemic, despite the occurrence of large WNV outbreaks with 
substantial morbidity and mortality and despite a growing need to monitor other 
arboviruses that pose an increasing public health threat. 
4. Many public health laboratory testing programs and mosquito/environmental 
surveillance programs for WNV have reached a tipping point where further 
funding reductions are likely to result in their loss entirely in some states. 
5. Although many state and surveyed LHDs have made substantial funding 
investments in WNV surveillance and control, some are entirely dependent on 
ELC WNV funding. In those jurisdictions where a substantial state/local 
investment has been made, ELC WNV funding remains critical to sustain current 
capacity, including in LHDs with no direct ELC funding.  
6. The capacity to conduct surveillance for other mosquito-borne viruses is patchy, 
with a few states having high-level capacity, but many having little to none. In 
particular, public health laboratory capacity for proactive surveillance is poor to 
non-existent in most states.  
7. LHDs with a historically high WNV burden play a key role in mosquito 
surveillance and control and in supporting surveillance for human WNV disease. 
Among LHDs with historically high WNV incidence, surveillance capacity is 
higher in agencies with direct ELC funding than in agencies without direct 
funding.  
8. Most states and ELC-funded LHDs need additional support to conduct full 
surveillance for WNV and other mosquito-borne viruses (including dengue). State 
and ELC-supported LHD respondents cite a need for an additional 137.6 FTE 
staff, a 58% increase in current staffing levels. The 15 responding LHDs with 
historically high WNV incidence but no direct ELC funding cite a need for an 
additional 49 FTE staff. 
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9. Responding LHDs with a historically high WNV burden all play an active role in 
mosquito control, particularly larviciding. Although some state health 
departments have provided funding to support local larviciding efforts, most do 





Based on these findings, CSTE—supported by ASTHO, NACCHO and APHL—
recommends that CDC take the following actions: 
 
 At a minimum, assure that current state and local health department capacity for 
WNV surveillance is maintained to assure not just state-level, but a national 
infrastructure for WNV and arboviral surveillance. Sufficient funding through the 
ELC cooperative agreement is needed for this: level funding will result in further 
erosion of capacity.  
 Secure additional support to distribute through the ELC cooperative agreement to: (a) 
expand mosquito-based surveillance in metropolitan areas with a historically large 
WNV disease burden (as many have reduced mosquito surveillance and a third have 
no mosquito surveillance capacity whatsoever) and (b) build sufficient capacity to 
conduct surveillance in all states for other endemic arboviruses (e.g., EEE, SLE, 
WEE, LaCrosse, Powassan viruses) and for emerging arboviral threats (e.g., dengue, 
Chikungunya, Japanese encephalitis, Zika, Heartland viruses). This includes having 
the public health laboratory capacity in most states to assure they routine test for and 
monitor the incidence of other arboviruses as is now done for WNV.   
 Contingent on the availability of additional funding, expand core ELC cooperative 
agreement objectives to include the following enhanced capacities to monitor 
endemic arboviruses and to detect and respond to the introduction of exotic 
arboviruses: 
o All ELC recipients should have WNV surveillance and control plans, and as 
appropriate to local risk, surveillance and control plans for other arboviruses. 
o Mosquito-based surveillance should be included in the programs for 
metropolitan areas with historically high WNV burden. 
o Diagnostic human specimens (cerebrospinal fluid and sera) submitted for 
WNV testing should be routinely tested for other endemic and exotic 
arboviruses, depending on the clinical syndrome, exposure history and local 
vector populations.  
Without additional funding, however, ELC-funded jurisdictions cannot be 
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Tables S1-S16: State 2012 data, comparison with 2004 where possible 
 
Table S1. Number  of state-level WNV surveillance staff with specified levels of 
training, regardless of funding source, 2012 and 2004  
Year State employees  Contracted employees 
 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 
Number of staff with DVM, MD/DO, RN or other clinical degrees 
2012 4 9 44 0 0 2 
2004 18 17 66 1 7 5 
Number of staff with PhD, DrPH, MSPH, MPH degrees in epidemiology 
2012 27 7 37 3 1 2 
2004 26 18 19 3 2 2 
Number of staff with PhD or Master’s degree in related sciences 
2012 31 13 38 2 3 13 
2004 46 17 36 6 7 21 
Number of other staff in clerical, administrative or other programmatic 
categories 
2012 49 33 125 12 12 36 




Table S2. Number and percentage of states with WNV surveillance staff with 
specified levels of training, funded by non-CDC sources, and median number of 
such staff, 2012 (N=50)  
 State employees  Contracted employees 
 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 
N (%) states with staff with DVM, MD/DO, RN or other clinical degrees 
No. (%) 2 (4) 2 (4) 13 (26) 0 (0) 0 (0) 1 (2) 
Median # 
staff 
1.5 4 2 - - 1 
N (%) states with staff with PhD, DrPH, MSPH, MPH degrees in 
epidemiology 
No. (%) 4 (8) 3 (6) 7 (14) 0 (0) 0 (0) 1 (2) 
Median # 
staff 
3.5 1 2 - - 1 
N (%) of states with staff with PhD or Master’s degree in related sciences 
No. (%) 5 (10) 8 (16) 9 (18) 2 (4) 0 2 (4) 
Median # 
staff 
2  1 3 2 - 1.5 
N (%) of states with staff in clerical, administrative or other programmatic 
categories 
No. (%) 8 (16) 8 (16) 18 (26) 1 (2) 1 (2) 3 (6) 
Median # 
staff 




Table S3. Number of WNV surveillance staff with specified levels of training, by 
funding source, 2012 (N=50)  
Year State employees  Contracted employees 
 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 
Number of staff with DVM, MD/DO, RN or other clinical degrees 
Total 4 9 44 - - 2 
Other 3 8 25 - - 1 
CDC* 1 1 19 - - 1 
Number of staff with PhD, DrPH, MSPH, MPH degrees in epidemiology 
Total 27 7.0 37 3 1 2 
Other 27 2.5 11 - - 1 
CDC* 0 4.5 26 3 1 1 
Number of staff with PhD or Master’s degree in related sciences 
Total 31 13 38 2 3 13 
Other 17 10 20 2 -   3 
CDC* 14   3 18 0 3 10 
Number of staff in clerical, administrative or other programmatic categories 
Total 49.0 33 125 12 12 36 
Other 32.8 20   59   1   1 11 
CDC* 16.2 13   66 11 11 25 
* Calculated by subtracting “other” from “total” (not asked directly). 
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Table S4. Number of FTE positions for WNV surveillance by functional role and 
need for additional positions  
 Number of FTE 
epidemiologists 
Number of FTE 
laboratory staff 






































27 18.2 0.67 30 29.8 0.99 28 20.3 0.73 19 8.2 0.43 
Additional 
needed 










49 59.7 1.22 49 91.0 1.86 49 110.8 2.26 49 70.0 1.43 
 
* N =  # responding states 
 
Table S5. Specialists working for state health departments, 2004 and 2012 
Does your agency have 
adequate access to: 
2012 In 2004 
N Yes (%) N Yes (%) 
Medical entomologist 
within public health 
agency 
50 16 (32) 49 20 (41) 
Medical entomologist 
through contract with 
another agency 
48 18 (38) 47 23 (49) 
Expertise in wildlife 
biology within your 
agency 
50 38 (76) 49 45 (92) 
Designated state public 
health veterinarian 
within your agency 





Table S6. Number and percentage of states with selected surveillance systems for 
WNV, their duration and whether have an active component, 2012 and 2004 
 N Conduct state-
level 
surveillance 










2012 50 49 (98) 12 6-12 28 
2004 49 49 (100) 12 5-12 47 
Equine disease 
2012 49 44 (90) 12 4-12   4 
2004 49 46 (94) 12 5-12 23 
Avian mortality 
2012 49 19 (39) 7 4-12   4 
2004 49 48 (98) 7 2-12 42 
Mosquito surveillance 
2012 49 39 (80) 5 2-12  




Table S7. Human WNV surveillance and reporting in states, 2012 and 2004 
 2012 2004 
N Yes (%) N Yes (%) 
To encourage reporting and to suggest a high index of suspicion for arboviral 
encephalitis, did your agency contact 
- neurologists 48 24 (50) 48 29 (60) 
- critical care specialists 48 23 (48) 49 28 (57) 
- ID specialists 48 28 (58) 49 40 (82) 
- Emergency depts. 49 28 (57) - - 
Did your agency require reporting    
- of hospitalized 
encephalitis cases of 
unknown etiology? 
50 24 (48) 49 31 (63) 
- of hospitalized 
meningitis cases of 
unknown etiology? 
50 25 (50) 49 27 (55) 
- from in-state 
laboratories? 
49 49 (100) 48 32 (67) 
In order to count a case of WNV as confirmed or probable, did your agency 




50 18 (36) 46 37 (80) 
- use the CDC/CSTE 
NPHSS case definition?  
50 44 (88) 49 43 (88) 
Was end of the year surveillance done to identify unreported human WNV cases by 
- auditing hospital or 
commercial labs? 
50 3 (6) - - 
- reviewing hospital 
discharge data? 
50 1 (2) - - 
What was the median interval in days between: 
 N Median (range) N Median (range) 
- date WNV-positive 
human specimen 
collected and data 
reported to WNV 
surveillance program? 
39 6 (1.5-17) 35 7 (2-28) 
- date of onset of the 
case and date case 
reported to ArboNET? 




Table S8a. Equine WNV surveillance and reporting in states, 2004 and 2012 
 2012 2004 
Yes 
(%) 




No (%) Unk (%) 
System in place for 
reporting cases of 
equine neurologic 
disease to the 
state health 
department? 
44 (88) 5 (10) 1 (2) 41 (84) 8 (16)  
If yes, were specimens submitted for diagnostic testing for: 
- WNV 37 (84) 6 (14) 1 (2) 38 (97) 1 (3)  
- other arboviruses 29 (66) 9 (21) 6 (14) 30 (77) 6 (15) 3 (8) 
- rabies 39 (89) 2 (5) 3 (7) 35 (90) 2 (5) 2 (5) 
Temporal-geographic clusters (2 or more cases) of equine neurologic disease 
 N Yes (%)  N Yes (%)  
Were clusters 
reported to your 
agency? 
44 10 (23)  47 13 (28)  
If yes, how many? 10 4.3 (mean)  11 1.7 (mean)  
Did your program 





10 5 (50)  13 6 (62)  















- other arboviruses 25 8 (0-332) 39 0 (0-263) 




Table S8b. Avian WNV surveillance and reporting in states, 2004 and 2012 
 2012 2004 
 N Yes (%)  N Yes (%)  
Maintain a 
database of dead 
bird sightings? 
49 12 (24)  49 28 (57)  
If state maintained a database of dead bird sightings 
- were specimens 
submitted for WNV 
testing? 
12 11 (92)    28 27 (93)   
- How many 
specimens tested?  





   
What strategies did your agency use for collecting and testing dead birds? 
- Collected all 
dead birds in an 
area all season 
12 3 (25)     
- Tested all dead 
birds in an area all 
season 
12 3 (25)     
- Collected all in an 
area until first tests 
positive 
12 1 (8)     
- Tested all in an 
area until the first 
tests positive 
12 1 (8)     
- Collected all of 
specified species 
all season long 
12 4 (33)     
- Tested all of 
specified species 
all season long 
12 3 (25)     
- Collected all of 
specific species 
until first tests + 
12 2 (17)     
- Tested all of 
specific species 
until first tests + 
12 3 (25)     
What was the median interval in days between a bird being collected and testing 
positive? 
 N Median Range N Median Range 




Table S9. Mosquito surveillance for WNV in states, 2012 and 2004 
 2012 2004 
N Yes (%) No (%) N Yes (%) No (%) 
Does the state collect information about mosquito surveillance in LHDs? 
 49 44 (88)  4 (8) 49 46 (94) 3 (6) 
If yes,  
 N Yes (%) 
 
Unk (%) N Yes (%) 
 
Unk (%) 
Do most LHDs in 
your state conduct 
adult mosquito 
surveillance? 
44 15 (34) 0 44 21 (48) 0 
Do most conduct 
larval mosquito 
surveillance? 
44 8 (18) 0 44 13 (30) 0 
Do you receive 
reports with 
mosquito species 
identified or does 
your lab identify the 
species? 
43 37 (86) 0 45 36 (80) 2 (4) 
Does your agency 
calculate minimal 
mosquito infection 
rates or receive 
such data? 
44 18 (41) 0 44 25 (47) 1 (2) 
 N median range unk N Median range unk 
What % of the population in your state lives in an area covered by mosquito 
surveillance? 
 43 50 (6-100) 5 
(12) 
37 65 5-100 6 
(16) 
Number of trap-nights mosquitos collected 












Table S10. Laboratory aspects of arboviral mosquito surveillance in states, 2012 
 N Yes (%) No (%) 
What labs performed WNV testing on mosquito pools collected in your state? 
- State or state-funded lab 46 40 (87)  
- Local health department lab 46 12 (26)  
- Local mosquito control district 46 17 (37)  
- Mosquito surveillance done, but no 
testing 
46 4 (9)  
Not applicable (no mosquito surveillance) 50 4 (8)  
For what viruses are mosquito pools routinely tested, in addition to WNV? 
- EEE 45 22 (49)  
- SLE 45 24 (53)  
- California serogroup 45 13 (29)  
- Other 45 13 (29)  
- Not applicable (no testing done) 45 11 (24)  
Did your state lab or another state-funded lab perform testing for WNV on mosquito 
pools in 2008? 
 50 42 (84) 8 (16) 
Has the capacity of these labs to test mosquito pools diminished since 2008? 
 40 27 (68) 13 (33) 
If yes, how has it affected the number of pools tested for WNV? 
- No longer test any pools 27 3 (11)  
- Test fewer pools than before 27 22 (81)  
- Other 27 4 (15)  
Which agencies in your state monitor for pesticide resistance in mosquitos? 
- State health dept. or other state agency 49 3 (6)  
- Local health agencies/districts 49 9 (18)  
- No monitoring done 49 33 (67)  
- Don’t know 49 7 (14)  
Does your or another state agency conduct or fund sentinel chicken/bird surveillance for 
WNV and/or other arboviruses? 
 50 5 (10)  
If yes, for which viruses? 
- WNV 5 5 (100)  
- EEE 5 3 (60)  
- SLE 5 3 (60)  




Table S11.  WNV educational prevention activities in states, 2012 and 2004 
 2012 2004 
N Yes (%) N Yes (%) 
Which of the following WNV prevention messages and activities did your program use 
and promote? 
- Use of DEET-based/other repellents 50 49 (98) 49 49 (100) 
- Peri-residential source reduction 50 47 (94) 49 47 (96) 
- Personal protection measures 50 48 (96) 49 49 (100) 
- Notification of adulticiding activities 50 17 (34) 49 13 (27) 
- Modification of messages for lower 
literacy and non-English speaking 
audiences  
50 23 (46) 49 35 (71) 
Which of the following methods did your program use to provide WNV prevention 
information in 2012? 
- Press releases to electronic and 
printed media 
50 48 (96) 49 47 (96) 
- Public service announcements 50 20 (40) 49 31 (63) 
- Passive distribution of info brochures 50 40 (80) 49 44 (90) 
- Active distribution of info brochures 50 24 (48) 49 37 (76) 
- Town, community, neighborhood 
meetings 
50 15 (30) 49 30 (61) 
- Posting info on the home page of 
your agency website 
50 45 (90) 49 48 (98) 
- Door-to-door outreach in selected 
locations 
50 11(22) 49 11 (22) 




Table S12. Mosquito control activities in states, 2012 
Larviciding for WNV prevention N Yes (%) No (%)  Unk (%) 
Have you ever financially supported or 
conducted larviciding in local jurisdictions? 
47 26 (55) 21 (45)  
Did your state conduct or financially 
support larviciding in at least some local 
jurisdictions in 2012? 
48 15 (31) 32 (69)  
Might your state have supported larviciding 
in 2012 if it had sufficient funding? 
47 25 (53) 9 (19) 13 (28) 
Did any local jurisdiction conduct 
larviciding in 2012 using its own funding? 
50 39 (78) 7 (14) 4 (8) 
Adulticiding for WNV Prevention 
Does your state have a plan for WNV control that includes a threshold level of vector 
mosquito abundance/infection rate that would result in a recommendation for 
adulticiding? (N=48) 
 Yes – have a threshold not requiring any 
human cases of WNV 
 14 (29)   
Yes – have a threshold that requires 
concurrent human cases 
 1 (2)   
No – have a plan but no threshold  13 (27)   
No – do not have a formal plan for 
adulticiding in response to WNV 
 20 (42)   
Does your state have an emergency fund or a specified emergency funding mechanism 
for adult mosquito control for WNV or other arboviruses? 
 49 13 (27) 36 (73)  
Has this funding mechanism been used to 
pay for adulticiding for WNV control? 
12 7 (58) 5 (42)  
Has your state or a local jurisdiction in it ever done adulticiding for WNV control? 
 46 37 (80)  9 (20)  
If no, why not? 
- Never had a serious outbreak 9 5 (56)   
- Had threat that reached adulticiding 
threshold, but no funding 
4 1 (25)   
- Had threat that reached adulticiding 
threshold, but no public support 
4 1 (25)   
- Other 4 3 (75)   
Did your state conduct or provide support to LHDs in 2012 to conduct adulticiding for 
other mosquito-borne diseases? 
 48 5 (10) 43 (90)  
If yes, for which viruses? 
- EEE 5 4 (80)   
- Dengue 5 1 (20)   
- Other 5 0 (0)   
If no, would you have provided support if you had the funding? 
- Not applicable, no outbreak threat 43 16 (37)   
- Yes, outbreak threat but insufficient 
funding 
27 7 (26)   
Aedes aegypti 
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Is there a record of Ae aegypti mosquitoes 
being found in your state in the past 5 
years?  
50 18 (36) 29 (58) 3 (6) 
If yes,  do you have a written dengue 
surveillance and control plan should it be 
detected (again)? 
18 5 (28) 13 (72)  
 
Table S13. WNV laboratory testing capabilities in state labs, 2012 (N=46) and 2004 
(N=47) 









2012 93 48 22 2 13   
2004 100 72 21 19 49   
Equine 
2012 26 11 9 9 30   
2004 57 23 13 19 45   
Avian 
2012 9 4 0 4 39 0 4 
2004 9 2 6 13 77 7  
Sentinel 
2012 11 9 4 2 2   
2004 28 9 6 4 6   
Mosquito 
2012    13 72 7 11 
2004    23 79 21  
 2012 2004 
N Yes (%) N Yes (%) 
If your lab uses a PRNT test, how is it used? 
- All positive ELISAs 11 7 (64) 14 7 (50) 
- Early season and any unusual 
ELISAs 
11 1 (9) 14 3 (21) 
- Only on equivocal ELISAs 11 3 (27) 14 4 (29) 
If PRNT is not performed at your lab, where is it performed? 
- CDC 35 26 (74) 36 23 (64) 
- Another state’s public health lab 35 1 (3) 36 4 (11) 
- ELISA positives are not confirmed by 
PRNT 




Table S14. Arboviral laboratory testing capacity and experience in states, 2012 
 N Yes (%) 
 
Does your state have at least some WNV testing capacity and/or contract with a lab for 
arboviral testing services? 
- Yes, have own testing capacity 50 46 (92) 
- Yes, contract with another lab 50 2 (4) 
- No, depend on another state’s or regional or CDC lab 50 4 (8) 
Were all CSF specimens tested for WNV in the state lab 
also routinely tested for one or more other arboviruses? 
43 26 (60) 
 
If yes, which arboviruses? 
- EEE 26 12 (46) 
- SLE 26 24 (92) 
- WEE 26 6 (23) 
- LaCrosse 26 5 (19) 
- Powassan 26 2 (8) 
- Other 26 4 (15) 
Is additional training necessary for your lab staff to test for 
WNV and/or other arboviruses? 
43 12 (28) 
For each of the following arboviruses, does your lab perform any testing and if so, what 
was the total number of CSF and/or serologic specimens tested for infection your lab in 
2012 and how many were positive? 
Arbovirus Perform testing Number 
tested  
Number  
Positive Yes  No  










Chikungunya  2 (5) 37 (95) 1 12 1 0 
Colorado tick fever 2 (5) 37 (95) 2 139 2 2 
Dengue 9 (23) 31 (78) 8 328 7 137 
EEE 24 (59) 17 (41) 18 4,766 16 23 
Japanese encephalitis 1 (3) 38 (97) 0 - 0 - 
LaCrosse 16 (42) 22 (58) 14 3,372 12 120 
Powassan 4 (11) 34 (89) 3 1,257 2 61 
SLE 34 (79) 9 (21) 28 8,216 27 167 
WEE 16 (39) 25 (61) 14 3,888 9 1 
West Nile virus 45 (100) 0 (0) 39 19,178 38 2,795 
Yellow fever 2 (5) 37 (95) 2 2 1 2 





Table S15. Types of diagnostic tests for arboviruses and number of laboratories with 
specific diagnostic testing capacity for human specimens in 2012 (N=46 state labs) 
 
Virus 
ELISA MIA IFA 
PRNT* PCR* IgM* IgG* IgM IgG IgM IgG 
 
California serogroup† 8 2 0 0 11 8 4 8 
Chikungunya 1 1 0 0 1 2 2 1 
Colorado tick fever 1 1 0 0 1 2 2 1 
Dengue 7 5 0 0 1 2 2 10 
Eastern equine 
encephalitis 8 4 5 0 10 8 5 14 
Japanese encephalitis 1 1 0 0 0 1 1 1 
Powassan 2 2 1 1 0 1 2 2 
St. Louis encephalitis 13 7 18 2 9 8 10 15 
Western equine 
encephalitis 3 3 0 1 10 8 4 7 
West Nile 32 24 18 2 2 3 9 26 
Yellow fever 2 1 0 0 0 1 2 2 
 
*IgM=Immunoglobin M; IgG=Immunoglobulin G; PRNT=plaque reduction neutralization 





Table S16. Relationship of ELC WNV funding to selected surveillance capacities in 
states, 2012 and 2004 
Has ELC funding for WNV enhanced your agency’s capacity to conduct surveillance for 
other vector-borne diseases? 
 2012 2004 
N Yes (%) N Yes (%) 
Other mosquito-borne disease 44 41 (93) 47 46 (98) 
Tick-borne disease 43 25 (58) 43 16(37) 
Flea-borne disease 40 6 (15) 41    7 (17) 
How have you managed reductions to ELC funding for WNV surveillance in the past 5 
years? 
 N Yes (%) No (%) NA 
Eliminated dead bird surveillance 49 28 (57) 15 (31) 6 (12) 
Reduced dead bird surveillance 49 15 (31) 17 (35) 17 (35) 
Decreased number of mosquito trap 
sites 
50 29 (58) 15 (30) 6 (12) 
Decreased number of mosquito pools 
tested 
50 34 (68) 12 (24) 4 (8) 
Decreased number of WNV tests 
performed on human specimens 
48 22 (46) 24 (50) 2 (4) 
Other  11   
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Tables ELC1-16:  ELC-supported city/county health department 2012 data, 
comparison with 2004 where possible  
 
Table ELC1. Number of WNV surveillance staff in ELC-supported LHDs with 
specified levels of training, regardless of funding source, 2012 and 2004 
Year LHD employees  Contracted employees 
 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 
Number of staff with DVM, MD/DO, RN or other clinical degrees 
2012 3 2 4 0 0 0 
2004 1 2 3 0 0 0 
Number of staff with PhD, DrPH, MSPH, MPH degrees in epidemiology 
2012 1 6 5 1 0 0 
2004 3 4 9 0 0 0 
Number of staff with PhD or Master’s degree in related sciences 
2012 6 1 4 0 0 1 
2004 10 1 0 0 0 0 
Number of other staff in clerical, administrative or other programmatic 
categories 
2012 2 6 11 0 1 5 




Table ELC2. Number of ELC-supported LHDs with WNV surveillance staff with 
specified levels of training, funded by non-CDC sources, and median number of 
such staff, 2012 (N=6)  
 LHD employees  Contracted employees 
 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 
Number of ELC-supported LHDs with staff with DVM, MD/DO, RN or other 
clinical degrees 
No. (%) 1 1 2 0 0 0 
Median # 
staff 
1 1 4 - - - 
Number of ELC-supported LHDs with staff with PhD, DrPH, MSPH, MPH 
degrees in epidemiology 
No. (%) 1 4 1 0 0 0 
Median # 
staff 
1 1.5 1 - - - 
Number of ELC-supported LHDs with staff with PhD or Master’s degree in 
related sciences 
No. (%) 1 1 2 0 0 1 
Median # 
staff 
2 1 2 0 0 1 
Number of ELC-supported LHDs with staff in clerical, administrative or 
other programmatic categories 
No. (%) 2 1 4 0 1 1 
Median # 
staff 




Table ELC3. Number of WNV surveillance staff in ELC-supported LHDs with 
specified levels of training, by funding source, 2012 (N=6)  
Year State employees  Contracted employees 
 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 
Number of staff with DVM, MD/DO, RN or other clinical degrees 
CDC 
grants 
2 1 0 - - - 
Other 1 1 4 - - - 
Total 3 2 4 0 0 0 
Number of staff with PhD, DrPH, MSPH, MPH degrees in epidemiology 
CDC 
grants 
0 0 4 1 - - 
Other 1 6 1 0 - - 
Total 1 6 5 1 0 0 
Number of staff with PhD or Master’s degree in related sciences 
CDC 
grants 
4 0 0 - - 0 
Other 2 1 4 - - 1 
Total 6 1 4 - - 1 
Number of staff in clerical, administrative or other programmatic categories 
CDC 
grants 
0 1 0 - 0 0 
Other 2 5 11 - 1 5 




Table ELC4. Number of FTE positions in ELC-supported LHDs for WNV surveillance by 
functional role and need for additional ones (N=6 ) 
 Number of FTE 
epidemiologists 
Number of FTE 
laboratory staff 



































4 4.8 1.2 4 1.9 0.5 3 12.9 4.3 2 1.4 0.7 
Additional 
needed 









6 9.9 1.7 4 4.9 1.2 6 22.6 3.8 6 5.5 0.9 
 
 
Table ELC5. Specialists working for ELC-supported LHDs, 2012 and 2004 
Does your LHD have 
adequate access to: 
2012 In 2004 
N Yes (%) N Yes (%) 
Medical entomologist 
within public health 
agency 
6 3 (50) 6 5 (83) 
Medical entomologist 
through contract with 
another local agency 
6 3 (50) 4 1 (25) 
Expertise in wildlife 
biology within a 
city/county agency 
6 3 (50) 6 4 (67) 
Designated state public 
health veterinarian 
within your agency 




Table ELC6. Number and percentage of ELC-supported LHDs with selected 
surveillance systems for WNV, their duration and whether have an active component, 
2012 and 2004 
 N Conduct local-
level 
surveillance 










2012 6 6 (100) 12 3-13 33% 
2004 6 6 (100) Mean 10.8  83 
Equine disease 
2012 5 1 (20) 12 12 0 
2004 6 3 (50) Mean 6.3  25 
Avian mortality 
2012 6 4 (67) 9 6-12 100% 
2004 6 6 (100) Mean 8.2  17 
Mosquito surveillance 
2012 6 6 (100) 7 3-12  




Table ELC7. Human WNV surveillance and reporting in ELC-supported LHDs, 2012 and 
2004 
 2012 2004 
N Yes (%) N Yes (%) 
To encourage reporting and to suggest a high index of suspicion for arboviral 
encephalitis, did your agency contact 
- neurologists 6 5 (83) 6 6 (100) 
- critical care specialists 6 5 (83) 6 6 (100) 
- ID specialists 6 6 (100) 6 6 (100) 
- Emergency depts. 6 6 (100) - - 
Did your agency (or state through your agency) require reporting    
- of hospitalized 
encephalitis cases of 
unknown etiology? 
6 4 (67) 6 6 (100) 
- of hospitalized 
meningitis cases of 
unknown etiology? 
6 4 (67) 6 6 (100) 
- from in-state 
laboratories? 
6 6 (100) 5 5 (100) 
In order to count a case of WNV a confirmed or probable, did your agency 




6 4 (67) 6 5 (83) 
- use the CDC/CSTE 
NPHSS case definition?  
6 5 (83) 6 4 (67) 
Was end of the year surveillance done to identify unreported human WNV cases by 
- auditing hospital or 
commercial labs? 
6 0 - - 
- reviewing hospital 
discharge data? 
6 0 - - 
What was the median interval in days between: 
 N Median (range) N Median (range) 
- date WNV-positive 
human specimen 
collected and data 
reported to WNV 
surveillance program? 




Table ELC8a. Equine WNV surveillance and reporting in ELC-supported LHDs, 2004 
and 2012 
 2012 2004 
Yes 
(%) 




No (%) Unk (%) 
System in place for 
reporting cases of 
equine neurologic 
disease to the 
state health 
department? 
2 (33) 4 (67)  2 (33) 4 (67)  
If yes, were specimens submitted for diagnostic testing for: 
- WNV 0 1 (50) 1 (50) 1 (50) 1 (50) 0 
- other arboviruses 0 1 (50) 1 (50) 0 2 (100) 0 
- rabies 1 (50) 0 1 (50) 0 2 (100) 0 
Temporal-geographic clusters (2 or more cases) of equine neurologic disease 
 N Yes (%)  N Yes (%)  
Were clusters 
reported to your 
agency? 
3 0   4 0  
How many equine specimens were tested in the city/county public health, state or other 










- WNV 1 1 1    
- other arboviruses 0 - -    




Table ELC8b. Avian WNV surveillance and reporting in ELC-supported LHDs, 2004 and 
2012 
 2012 2004 
 N Yes (%)  N Yes (%)  
Maintain a 
database of dead 
bird sightings? 
6 3 (50)  6 4 (67)  
If maintained a database of dead bird sightings 
- Were specimens 
submitted for WNV 
testing? 
3 3 (100)    4 4 (100)   
- How many 





   
What strategies did your agency use for collecting and testing dead birds? 
- Collected all 
dead birds in an 
area all season 
3 1 (33)     
- Tested all dead 
birds in an area all 
season 
3 1 (33)     
- Collected all in an 
area until first tests 
positive 
3 0     
- Tested all in an 
area until the first 
tests positive 
3 0     
- Collected all of 
specified species 
all season long 
3 0     
- Tested all of 
specified species 
all season long 
3   1 (33)     
- Collected all of 
specific species 
until first tests + 
3 0     
- Tested all of 
specific species 
until first tests + 
3 0     
What was the median interval in days between a bird being collected and testing 
positive? 
 N Median Range N Median Range 




Table ELC9. Mosquito surveillance for WNV in ELC-supported LHDs, 2012 and 2004 
 2012 2004 
N Yes (%) No (%) N Yes (%) No (%) 
Collect information for mosquito surveillance? 
 4 4 (100) 0  6 4 (67) 2 (33) 
If yes,  
 N Yes (%) 
 
Unk (%) N Yes (%) 
 
Unk (%) 
Does your LHD or 




3 3 (100) 0 4 4 (100) 0 
Does your LHD or 









6 5 (83) 0 4 4 (100) 0 
Does your agency 
calculate minimal 
mosquito infection 
rates or receive 
such data? 
6 5 (83) 0 4 3 (75) 0 
Do you trap at fixed 
sites most of the 
WNV season? 
3 3 (100) 0    
If yes, how often was trapping done at most of these sites in 2012? 
- every 7 days 3 1 (33)     
- every 14 days 3 0     
- other 3 2 (67)     
 N median range unk N Median range unk 
What % of the population in your jurisdiction lives in an area covered by mosquito 
surveillance? 
 3 100 100-
100 
- 3 100 100 0 
Number of trap-nights adult mosquitos collected 
 3 300 
(mean) 







Table ELC10. Laboratory aspects of arboviral mosquito surveillance in ELC-supported 
LHDs, 2012 
 N Yes (%) No (%) 
What lab performed WNV testing on mosquito pools collected in your jurisdiction? 
- City/county health-dept. lab 6 4 (67)  
- Local mosquito control district lab 6 0   
- State health or other state agency lab 6 2 (33)  
- Mosquito surveillance done, but no 
testing 
6 0  
Not applicable (no mosquito surveillance) 6 0  
For what viruses are mosquito pools routinely tested in addition to WNV? 
- EEE 6 0  
- SLE 6 2 (33)  
- California serogroup 6 0  
- Other 6 1 (17)  
- Not applicable (no testing done) 6 0  
Did your local public health lab or another locally-funded lab perform testing for WNV on 
mosquito pools in 2008? 
 5 4 (80) 1 (20) 
If yes, has the capacity of these labs to test mosquito pools diminished since 2008? 
 3 1 (33) 2 (67) 
If yes, how has it affected the number of pools tested for WNV? 
- No longer test any pools 1 0  
- Test fewer pools than before 1 1 (100)  
- Other 1 0  
Does your agency map larval breeding 
sites? 
6 3 (50)  
Does your agency evaluate adult 
mosquito control using caged 
mosquitoes in sprayed areas? 
6 1 (17)  
Does your or another local agency 
monitor for pesticide resistance in 
mosquitos? 




Table ELC11.  WNV educational prevention activities in ELC-supported LHDs, 
2012 and 2004 
 2012 2004 
N Yes (%) N Yes (%) 
Which of the following WNV prevention messages and activities did your program use 
and promote? 
- Use of DEET-based/other repellents 6 6 (100) 6 6 (100) 
- Peri-residential source reduction 6 6 (100) 6 6 (100) 
- Personal protection measures 6 6 (100) 6 6 (100) 
- Notification of adulticiding activities 6 4 (67) 6 5 (83) 
- Modification of messages for lower 
literacy and non-English speaking 
audiences  
6 6 (100) 6 5 (83) 
Which of the following methods did your program use to provide WNV prevention 
information in 2012? 
- Press releases to electronic and 
printed media 
6 6 (100) 6 6 (100) 
- Public service announcements 6 4 (67) 6 4 (67) 
- Passive distribution of info brochures 6 5 (83) 6 5 (83) 
- Active distribution of info brochures 6 5 (83) 6 6 (100) 
- Town, community, neighborhood 
meetings 
6 4 (67) 6 6 (100) 
- Posting info on the home page of 
your agency website 
6 6 (100) 6 6 (100) 
- Door-to-door outreach in selected 
locations 
6 3 (50) 6 3 (50) 




Table ELC12. Mosquito control activities in ELC-supported LHDs, 2012 
Larviciding for WNV prevention N Yes (%) No (%)  Unk (%) 
Has your city/county ever financially 
supported or conducted larviciding to 
prevent WNV in your jurisdiction? 
5 4 (80)   
Did your city/county conduct or financially 
support larviciding in at least some 
locations in 2012? 
5 3 (60)   
Might your city/county have supported 
larviciding in 2012 if it had sufficient 
funding? 
5 3 (60)   
Adulticiding for WNV Prevention 
Does your city/county have a plan for WNV control that includes a threshold level of 
vector mosquito abundance/infection rate that would result in a recommendation for 
adulticiding? 
No – no local plan, defer to state plan   1 (20)   
 Yes – have a threshold not requiring any 
human cases of WNV 
 4 (80)   
Yes – have a threshold that requires 
concurrent human cases 
 0   
No – have a plan but no threshold  0   
No – do not have a formal plan for 
adulticiding in response to WNV 
 0   
Does your jurisdiction have an emergency fund or a specified emergency funding 
mechanism for adult mosquito control for WNV or other arboviruses? 
 5 2 (40) 3 (60)  
Has this funding mechanism been used to 
pay for adulticiding for WNV control? 
2 1 (50) 1 (50)  
Has your jurisdiction ever done adulticiding for WNV control? 
 6 5 (83) 1 (17)  
If no, why not? 
- never had a serious outbreak 1 0   
- had threat that reached adulticiding 
threshold, but no funding 
1 0   
- had threat that reached adulticiding 
threshold, but no public support 
1 0   
- Other 1 1   
Did your city/county conduct adulticiding for other mosquito-borne diseases in 2012? 
 5 0 5 (100)  
If no, would you have provided support if you had the funding? 
- Not applicable, no outbreak threat 5 3 (60)   
- Yes, outbreak threat but insufficient 
funding 
5 1 (20)   
Aedes aegypti 
Is there a record of Ae aegypti mosquitoes 
being found in your jurisdiction in the past 
5 years?  
6 3 (50) 2 (33) 1 (17) 
If yes,  do you have a written dengue 3 0   
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Table ELC13. (Q30) WNV laboratory testing capabilities in ELC-supported labs, 
2012 (N=4) and 2004 (N=6) 









2012 2 (50) 2 (50) 1 (25) 1 (25) 2 (50)   
2004 6 (100) 4 (67) 1 (17) 2 (33) 5 (83)   
Equine 
2012 0 0 0 0 0   
2004 2 (33) 0 0 1 (17) 1 (17)   
Avian 
2012 0 0 0 0 0 0 0 
2004 0 0 0 0 3 (50) 2 (33)  
Sentinel 
2012 0 0 0 0 0   
2004 1 (17) 0 0 0 0   
Mosquito 
2012    0 1 (25) 0 0 
2004    0 3 (50) 0  
 2012 2004 
N Yes (%) N Yes (%) 
If your lab uses a PRNT test, how is it used? 
- all positive ELISAs 2 1 (50) 2 1 (50) 
- early season and any unusual 
ELISAs 
2 1 (50) 2 1 (50) 
- only on equivocal ELISAs 2 0 (0) 2 0 (0) 
If PRNT is not performed at your lab, where is it performed? 
- CDC 3 1 (33) 5 3 (60) 
- Another state’s public health lab 3 2 (67) 5 2 (40) 
- ELISA positives are not confirmed by 
PRNT 




Table ELC14. Arboviral laboratory testing capacity and experience in ELC-supported 
LHDs, 2012 
 N Yes (%) 
 
Does your city/county have at least some WNV testing capacity and/or do you contract 
with a lab for arboviral testing services? 
- Yes, have own testing capacity 6 4 (67) 
- Yes, contract with another lab 6 0 
- No, depend on the state lab 6 2 (33) 
- No, depend on another lab 6 0 
Were all CSF specimens tested for WNV in the 
city/county lab also routinely tested for one or more other 
arboviruses? 
4 1 (25) 
If yes, which arboviruses? 
- EEE 1 0 
- SLE 1 1 
- WEE 1 0 
- LaCrosse 1 0 
- Powassan 1 0 
- Other 1 0 
Is additional training necessary for your lab staff to test for 
WNV and/or other arboviruses? 
3 0 
For each of the following arboviruses, does your lab perform any testing and if so, what 
was the total number of CSF and/or serologic specimens tested for infection your lab in 
2012 and how many were positive? 
Arbovirus Perform testing Number 
tested  
Number  
Positive Yes  No  










Chikungunya    3 0 - - 
Colorado tick fever   3 0 - - 
Dengue   3 3 1 2 
EEE   3 0   
Japanese encephalitis   3 0   
LaCrosse   3 0   
Powassan   3 0   
SLE   3 437 2 4 
WEE   3 6 1 0 
West Nile virus   3 582 2 161 
Yellow fever   3 0 - - 







Table ELC15.  Types of diagnostic tests for arboviruses and number of LHD 
laboratories with specific diagnostic testing capacity for human specimens in 2012* 
(N=4 ELC-supported city/county laboratories) 
 
Virus 
ELISA MIA IFA 
PRNT* PCR* IgM* IgG* IgM IgG IgM IgG 
 
California serogroup† 0 0 0 0 0 0 0 0 
Chikungunya 0 0 0 0 0 0 0 0 
Colorado tick fever 0 0 0 0 0 0 0 0 
Dengue 1 1 0 0 1 1 1 3 
Eastern equine 
encephalitis 1 1 0 0 0 0 1 1 
Japanese encephalitis 0 0 0 0 0 0 0 0 
Powassan 0 0 0 0 0 0 0 0 
St. Louis encephalitis 1 1 1 0 1 1 1 1 
Western equine 
encephalitis 0 0 0 0 1 1 0 0 
West Nile 3 3 1 0 2 2 1 3 
Yellow fever 0 0 0 0 0 0 0 0 
 
†Such as La Crosse or Jamestown Canyon viruses 
 
ELISA = Enzyme-linked immunosorbant assay 
MIA = Microsphere immunoassay 
IFA = Indirect immunoflourescent assay 
PRNT = Plaque reduction neutralization test 
PCR = Polymerase chain reaction 
IgM = Immunoglobulin M 
* IgM=Immunoglobin M; IgG=Immunoglobin G; PRNT=plaque reduction neutralization; 





Table ELC16. Relationship of ELC WNV funding to selected surveillance 
capacities in ELC-funded LHDs, 2012 and 2004 
Has ELC funding for WNV enhanced your agency’s capacity to conduct surveillance for 
other vector-borne diseases? 
 2012 2004 
N Yes* (%) N Yes (%) 
Other mosquito-borne disease 6 6 (100) 6 6 (100) 
Tick-borne disease 6 4 (67) 6 1 (17) 
Flea-borne disease 6 2 (33) 6 1 (17) 
How have you managed reductions to ELC funding for WNV surveillance in the past 5 
years? 
 N Yes (%) No (%) NA 
Eliminated dead bird surveillance 6 2 (50) 2 (50) 2  
Reduced dead bird surveillance 6 2 (50) 1 (25) 2 
Decreased number of mosquito trap 
sites 
6 3 (75) 1 (25) 2  
Decreased number of mosquito pools 
tested 
6 1 (25) 3 (75) 2 
Decreased number of WNV tests 
performed on human specimens 
6 1 (20) 4 (80) 1 
Other 6 0   
* Yes includes “highly,” “substantially,” “some” and “a little.” 
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Tables LHD 1-16:  Big city/county LHD data, comparison of ELC vs. non-
ELC-funded LHDs 
 
Table LHD1. Number  and percentage of ELC- (N=6) vs. non-ELC-funded LHDs 
(N=15) with WNV surveillance staff with specified levels of training, regardless of 
funding source,  
Year LHD employees  Contracted employees 
 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 
N (%) LHDs with staff with DVM, MD/DO, RN or other clinical degrees 
ELC 2 (33) 2 (33) 2 (33) 0 0 0 
Non-ELC 2 (13) 3 (20) 3 (20 0 0 0 
N (%) LHDs with staff with PhD, DrPH, MSPH, MPH degrees in epidemiology 
ELC 1 (17) 2 (33) 2 (33) 1 (17) 0 0 
Non-ELC 6 (40) 1 (7) 4 (27)   0 (0) 0 0 
N (%) LHDs with staff with PhD or Master’s degree in related sciences 
ELC 2 (33) 0 (0) 2 (33) 0 0 1 (17) 
Non-ELC 5 (33) 2 (13) 2 (13) 0 0 0 
N (%) of LHDs with staff in clerical, administrative or other programmatic 
categories 
ELC 2 (33) 2 (33) 3 (50) 0 1 (17) 1 (17) 




Table LHD2. Number and percentage of ELC- (N=6) and non-ELC-funded 
(N=15) LHDs with WNV surveillance staff with specified levels of training, funded 
by non-CDC sources, and median number of such staff, 2012  
 Employees of ELC-funded LHD  Employees of non-ELC-funded 
LHD 
 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 
N (%) LHDs with staff with DVM, MD/DO, RN or other clinical degrees 
No. (%) 1 (17) 1 (17) 2 (33) 2 (13) 1 (7) 1 (7) 
Median # 
staff 
1  1  4  1.1 1 2 
N (%) LHDs with staff with PhD, DrPH, MSPH, MPH degrees in epidemiology 
No. (%) 1 (17) 4 (67) 1 (7) 6 (40) 0 (0) 3 (20) 
Median # 
staff 
1 1.5 1 1.5 1 2.5 
N (%) of LHDs with staff with PhD or Master’s degree in related sciences 
No. (%) 1 (17) 1 (17) 2 (33) 6 (40) 1 (7) 2 (13) 
Median # 
staff 
2 1 2 1 1 2.5 
N (%) of LHDs with staff in clerical, administrative or other programmatic 
categories 
No. (%) 2 (33) 1 (17) 4 (67) 5 (33) 1 (7) 5 (33) 
Median # 
staff 




Table LHD3. Number of WNV surveillance staff in ELC-funded and non-ELC-
funded LHDs with specified levels of training, by funding source, 2012  (N=6 and 
N=15 respectively) 
Year LHDs with ELC funding  LHDs without ELC funding 
 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 1.0FTE 0.5-0.99 
FTE 
<0.5 FTE 
Number of staff with DVM, MD/DO, RN or other clinical degrees 
CDC 
grants 
2 1 0 1.9 5 3 
Other 1 1 4 2.1 1 2 
Total 3 2 4 4 6 5 
Number of staff with PhD, DrPH, MSPH, MPH degrees in epidemiology 
CDC 
grants 
1 ? 4 5.9 2 2 
Other 1 6 1 12.1 0 5 
Total 2 3 5 18 2 7 
Number of staff with PhD or Master’s degree in related sciences 
CDC 
grants 
4 0 0 0 1 0 
Other 2 1 5 9 1 5 
Total 6 1 5 9 2 5 
Number of staff in clerical, administrative or other programmatic categories 
CDC 
grants 
0 1 0 1 1 1 
Other 2 6 16 5 1 5 





Table LHD4. Number of FTE positions in ELC-funded and non-ELC-funded LHDs 
for WNV surveillance by functional role and need for additional positions (N=6 and 
15, respectively ) 
 Number of FTE 
epidemiologists 
Number of FTE 
laboratory staff 




























6 6.9 1.2 6 1.9 0.5 6 15.6 2.6 6 3.5 0.6 
Additional 
needed 
4 3 0.8 4 3 0.8 3 7 2.3 2 2 1.0 
Optimal 
staffing 
6 9.9 1.7 4 4.9 1.2 6 21.6 3.6 6 5.5 0.9 
Non-ELC 
Current 
15 25.9 1.7 3 5.5 1.8 10 78.3 5.2 15 31.3 2.1 
Additional 
needed 
4 3.2 0.8 4 4.5 1.1 8 29.3 3.7 6 12.2 2.3 
Optimal 
staffing 
15 29.1 1.9 3 10.0 3.3 10 107.6 7.2 15 43.5 2.9 




Table LHD5. Specialists working for ELC-supported and nonELC LHDs, 2012  
Does your LHD have 
adequate access to: 
ELC-funded LHDs Non-ELC-funded LHDs 
N Yes (%) N Yes (%) 
Medical entomologist 
within public health 
agency 
6 3 (50) 14 4 (29) 
Medical entomologist 
through contract with 
another local agency 
6 3 (50) 13 4 (31) 
Expertise in wildlife 
biology within a 
city/county agency 
6 3 (50) 15 3 (20) 
Designated state public 
health veterinarian 
within your agency 




Table LHD6. Number and percentage of ELC-funded and non-ELC-funded LHDs 
with selected surveillance systems for WNV, their duration and whether have an 
active component, 2012  
 N Conduct local-
level 
surveillance 










ELC 6 6 (100) 12 3-13 33 
Non-
ELC 
15 0 (0) 12 4-12 53 
Equine disease 
ELC 5 1 (20) 12 12 0 
Non-
ELC 
14 2 (14) 12 12-12 17 
Avian mortality 
ELC 6 4 (67) 9 6-12 100% 
Non-
ELC 
15 3 (20) 12 (80) 12 5-12 
Mosquito surveillance 
ELC 6 6 (100) 7 3-12 - 
Non-
ELC 




Table LHD7. Human WNV surveillance and reporting in ELC-funded and non-ELC-
funded LHDs, 2012  
 ELC-funded LHDs Non-ELC-funded LHDs 
N Yes (%) N Yes (%) 
To encourage reporting and to suggest a high index of suspicion for arboviral 
encephalitis, did your agency contact 
- neurologists 6 5 (83) 15 5 (33) 
- critical care specialists 6 5 (83) 15 7 (47) 
- ID specialists 6 6 (100) 15 7 (47) 
- Emergency depts. 6 6 (100) 15 8 (53) 
Did your agency (or state through your agency) require reporting    
- of hospitalized 
encephalitis cases of 
unknown etiology? 
6 4 (67) 15 7 (47) 
- of hospitalized 
meningitis cases of 
unknown etiology? 
6 4 (67) 14 9 (64) 
- from in-state 
laboratories? 
6 6 (100) 15 13 (87) 
In order to count a case of WNV a confirmed or probable, did your agency 




6 4 (67) 14 8 (57) 
- use the CDC/CSTE 
NPHSS case definition?  
6 5 (83) 14 11 (79) 
Was end of the year surveillance done to identify unreported human WNV cases by 
- auditing hospital or 
commercial labs? 
6 0 15 1 (7) 
- reviewing hospital 
discharge data? 
6 0 15 1 (7) 
What was the median interval in days between: 
 N Median (range) N Median (range) 
- date WNV-positive 
human specimen 
collected and data 
reported to WNV 
surveillance program? 




Table LHD8a. Equine WNV surveillance and reporting in ELC-funded and non-ELC-
funded LHDs, 2012 
 ELC-funded LHDs Non-ELC-funded LHDs 
Yes 
(%) 




No (%) Unk (%) 
System in place for 
reporting cases of 
equine neurologic 
disease to the 
state health 
department? 
2 (33) 4 (67) 2 (33) 4 (31) 9 (69)  
If yes, were specimens submitted for diagnostic testing for: 
- WNV 0 1 (50) 1 (50) 3 (75) 0 1 (25) 
- other arboviruses 0 1 (50) 1 (50) 2 (50) 1 (25) 1 (25) 
- rabies 1 (50) 0 1 (50) 3 (75) 1 (25) 0 
Temporal-geographic clusters (2 or more cases) of equine neurologic disease 
 N Yes (%)  N Yes (%)  
Were clusters 
reported to your 
agency? 
3 0   4 1 (25)  
How many equine specimens were tested in the city/county public health, state or other 










- WNV 1 1 1 3 11 0-13 
- other arboviruses 0 - - 3 0 0-11 




Table LHDS8b. Avian WNV surveillance and reporting in ELC-funded and non-ELC-
funded LHDs, 2012 
 ELC-funded LHDs Non-ELC-funded LHDs 
 N Yes (%)  N Yes (%)  
Maintain a 
database of dead 
bird sightings? 
6 3 (50)  15 2 (13)  
If maintained a database of dead bird sightings 
- were specimens 
submitted for WNV 
testing? 
3 3 (100)    2 2 (100)   
- How many 
specimens tested?  
3 25 5-265 2 16 5-27 
What strategies did your agency use for collecting and testing dead birds? 
- Collected all 
dead birds in an 
area all season 
3 1 (33)  2 2 (100)  
- Tested all dead 
birds in an area all 
season 
3 1 (33)  2 2 (100)  
- Collected all in an 
area until first tests 
positive 
3 0  2 0  
- Tested all in an 
area until the first 
tests positive 
3 0  2 0  
- Collected all of 
specified species 
all season long 
3 0  2 0  
- Tested all of 
specified species 
all season long 
3   1 (33)  2 0  
- Collected all of 
specific species 
until first tests + 
3 0  2 0  
- Tested all of 
specific species 
until first tests + 
3 0  2 0  
What was the median interval in days between a bird being collected and testing 
positive? 
 N Median Range N Median Range 




Table LHD9. Mosquito surveillance for WNV in ELC-funded and non-ELC-funded LHDs, 
2012 
 ELC-funded LHDs Non-ELC-funded LHDs 
N Yes (%) No (%) N Yes (%) No (%) 
Collect information for mosquito surveillance? 
 4 4 (100) 0  15 10 (67) 5 (33) 
If yes,  
 N Yes (%) 
 
Unk (%) N Yes (%) 
 
Unk (%) 
Does your LHD or 




3 3 (100) 0 10 10 (100) 0 
Does your LHD or 









6 5 (83) 0 10 9 (90) 0 
Does your agency 
calculate minimal 
mosquito infection 
rates or receive 
such data? 
6 5 (83) 0 10 5 (50) 0 
Do you trap at fixed 
sites most of the 
WNV season? 
3 3 (100) 0 10 9 (90) 0 
If yes, how often was trapping done at most of these sites in 2012? 
- every 7 days 3 1 (33)  9 6 (67)  
- every 14 days 3 0  9 0  
- other 3 2 (67)  9 3 (33)  
 N median range unk N Median range unk 
What % of the population in your jurisdiction lives in an area covered by mosquito 
surveillance? 
 3 100 100-
100 
- 10 100 35-
100 
3 
Number of trap-nights adult mosquitos collected 
 3 300 
(mean) 









Table LHD10. Laboratory aspects of arboviral mosquito surveillance in ELC-funded and 
non-ELC-funded LHDs, 2012 
 ELC-funded LHDs Non-ELC-funded 
LHDs 
 N Yes (%) N Yes (%) 
What lab performed WNV testing on mosquito pools collected in your jurisdiction? 
- City/county health-dept. lab 6 4 (67) 10 3 (30) 
- Local mosquito control district lab 6 0  10 0 (0) 
- State health or other state agency lab 6 2 (33) 10 7 (70) 
- Mosquito surveillance done, but no 
testing 
6 0 10 1 (10) 
Not applicable (no mosquito surveillance) 6 0 15 5 (33) 
For what viruses are mosquito pools routinely tested in addition to WNV? 
- EEE 6 0 10 2 (20) 
- SLE 6 2 (33) 10 5 (50) 
- California serogroup 6 0 10 2 (20) 
- Other 6 1 (17) 10 3 (30) 
Did your local public health lab or another locally-funded lab perform testing for WNV on 
mosquito pools in 2008? 
 5 4 (80)            14  4 (29) 
If yes, has the capacity of these labs to test mosquito pools diminished since 2008? 
 3 1 (33) 4 0 
If yes, how has it affected the number of pools tested for WNV? 
- No longer test any pools 1 0 - - 
- Test fewer pools than before 1 1 (100) - - 
- Other 1 0 - - 
Does your agency map larval breeding 
sites? 
6 3 (50) 14 8 (57) 
Does your agency evaluate adult 
mosquito control using caged 
mosquitoes in sprayed areas? 
6 1 (17) 14 3 (21) 
Does your or another local agency 
monitor for pesticide resistance in 
mosquitos? 




Table LHD11.  WNV educational prevention activities in ELC-funded and non-ELC-
funded LHDs, 2012 
 ELC-funded LHDs Non-ELC-funded 
LHDs 
N Yes (%) N Yes (%) 
Which of the following WNV prevention messages and activities did your program use 
and promote? 
- Use of DEET-based/other repellents 6 6 (100) 15 14 (93) 
- Peri-residential source reduction 6 6 (100) 15 12 (80) 
- Personal protection measures 6 6 (100) 15 14 (93) 
- Notification of adulticiding activities 6 4 (67) 15 6 (40) 
- Modification of messages for lower 
literacy and non-English speaking 
audiences  
6 6 (100) 15 9 (60) 
Which of the following methods did your program use to provide WNV prevention 
information in 2012? 
- Press releases to electronic and 
printed media 
6 6 (100) 15 14 (93) 
- Public service announcements 6 4 (67) 15 4 (27) 
- Passive distribution of info brochures 6 5 (83) 15 13 (87) 
- Active distribution of info brochures 6 5 (83) 15 6 (40) 
- Town, community, neighborhood 
meetings 
6 4 (67) 15 6 (40) 
- Posting info on the home page of 
your agency website 
6 6 (100) 15 12 (80) 
- Door-to-door outreach in selected 
locations 
6 3 (50) 15 2 (13) 




Table LHD12. Mosquito control activities in ELC-funded and non-ELC-funded LHDs, 
2012 
 ELC-funded LHDs Non-ELC-funded 
LHDs 
Larviciding for WNV prevention N Yes (%) N Yes (%) 
Has your city/county ever financially 
supported or conducted larviciding to 
prevent WNV in your jurisdiction? 
5 4 (80) 14 14 (100) 
Did your city/county conduct or financially 
support larviciding in at least some 
locations in 2012? 
5 3 (60) 13 12 (92) 
Might your city/county have supported 
larviciding in 2012 if it had sufficient 
funding? 
5 3 (60) 8 1 (13) 
Adulticiding for WNV Prevention 
Does your city/county have a plan for WNV control that includes a threshold level of 
vector mosquito abundance/infection rate that would result in a recommendation for 
adulticiding? 
No – no local plan, defer to state plan  1 (20)  1 (7) 
 Yes – have a threshold not requiring any 
human cases of WNV 
 4 (80)  4 (29) 
Yes – have a threshold that requires 
concurrent human cases 
 0  1 (7) 
No – have a plan but no threshold  0  4 (29) 
No – do not have a formal plan for 
adulticiding in response to WNV 
 0  4 (29) 
Does your jurisdiction have an emergency fund or a specified emergency funding 
mechanism for adult mosquito control for WNV or other arboviruses? 
 5 2 (40) 14 4 (29) 
Has this funding mechanism been used to 
pay for adulticiding for WNV control? 
2 1 (50) 4  3 (75) 
Has your jurisdiction ever done adulticiding for WNV control? 
 6 5 (83) 14 9 (64) 
If no, why not? 
- never had a serious outbreak 1 0 5 1 (20) 
- had threat that reached adulticiding 
threshold, but no funding 
0 0 4 2 (50) 
- had threat that reached adulticiding 
threshold, but no public support 
0 0 4 2 (50) 
- Other 1 1 4 1 (25) 
Did your city/county conduct adulticiding for other mosquito-borne diseases in 2012? 
 5 0 13 4 (31) 
If yes, for which viruses? 
- EEE   4 1 (25) 
- dengue   4 1 (25) 
- other   4 2 (50) 
If no, would you have provided support if you had the funding? 
- Not applicable, no outbreak threat 5 3 (60) 9 8 (89) 
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- Yes, outbreak threat but insufficient 
funding 
3 1 (33) 1 1 (100) 
Aedes aegypti 
Is there a record of Ae aegypti mosquitoes 
being found in your jurisdiction in the past 
5 years?  
6 3 (50) 15 6 (40) 
If yes,  do you have a written dengue 
surveillance and control plan should it be 
detected (again)? 




Table LHD13.  WNV laboratory testing capabilities in ELC-funded and non-ELC-
funded labs, 2012 (N=4 and 2, respectively) 









ELC 2 (50) 2 (50) 1 (25) 1 (25) 2 (50)   
Non-
ELC 
1 (50) 1 (50) 0 (0) 0 (0) 0 (0)   
Equine 
ELC 0 0 0 0 0   
Non-
ELC 
0 0 0 0 0   
Avian 
ELC 0 0 0 0 0 0 0 
Non-
ELC 
0 0 0 0 0 0  
Sentinel 
ELC 0 0 0 0 0   
Non-
ELC 
1 (17) 0 0 0 0   
Mosquito 
ELC    0 1 (25) 0 0 
Non-
ELC 
   0 1 (50) 0  
 ELC-funded labs Non-ELC-funded labs 
N Yes (%) N Yes (%) 
If your lab uses a PRNT test, how is it used? 
- all positive ELISAs 2 1 (50) 1 0 
- early season and any unusual 
ELISAs 
2 1 (50) 1 0 
- only on equivocal ELISAs 2 0 (0) 1 1 (100) 
If PRNT is not performed at your lab, where is it performed? 
- CDC 3 1 (33) 2 1 (50) 
- another state’s public health lab 3 2 (67) 2 1 (50) 
- ELISA positives are not confirmed by 
PRNT 





Table LHD14 Arboviral laboratory testing capacity and experience in non-ELC-
funded LHDs, 2012 
 N Yes (%) 
 
Does your city/county have at least some WNV testing capacity and/or do you contract 
with a lab for arboviral testing services? 
- Yes, have own testing capacity 14 2 (14) 
- Yes, contract with another lab 14 0 
- No, depend on the state lab 14 10 (71) 
- No, depend on another lab 14 2 (14) 
Were all CSF specimens tested for WNV in the state lab 
also routinely tested for one or more other arboviruses? 
4 0 
Is additional training necessary for your lab staff to test for 
WNV and/or other arboviruses? 
4 0 
For each of the following arboviruses, does your lab perform any testing and if so, what 
was the total number of CSF and/or serologic specimens tested for infection your lab in 
2012 and how many were positive? 
Arbovirus Perform testing Number 
tested  
Number  
Positive Yes  No  












West Nile virus 2 13 2 148 2 71 




Table LHD15. Types of diagnostic tests for arboviruses and number of LHD 
laboratories with specific diagnostic testing capacity for human specimens in 2012* 
(N=2 city/county labs) 
 
Virus 
ELISA MIA IFA 
PRNT PCR IgM IgG IgM IgG IgM IgG 
West Nile 1 (50) 1 (50) 0 0 1 (50) 1 (50) 0 1 (50) 
All other mosquito-borne 0 0 0 0 0 0 0 0 
 
ELISA = Enzyme-linked immunosorbant assay 
MIA = Microsphere immunoassay 
IFA = Indirect immunoflourescent assay 
PRNT = Plaque reduction neutralization test 
PCR = Polymerase chain reaction 
IgM = Immunoglobulin M 




Table LHD16. Relationship of ELC WNV funding to selected surveillance 
capacities in ELC-funded and non-ELC-funded LHDs, 2012 
Has ELC funding for WNV enhanced your agency’s capacity to conduct surveillance for 
other vector-borne diseases? 
 ELC-funded LHDs Non-ELC-funded LHDs 
N Yes* (%) N Yes (%) 
Other mosquito-borne 6 6 (100) 13 4 (31) 
Tick-borne  6 4 (67) 13 2 (15) 
Flea-borne  6 2 (33) 13 1 (8) 
How have you managed reductions to ELC funding for WNV surveillance in the past 5 
years? 
 N** Yes (%) N Yes (%) 
Eliminated dead bird surveillance 4 2 (50) 6 4 (67) 
Reduced dead bird surveillance 4 2 (50) 4 3 (75) 
Decreased number of mosquito trap 
sites 
4 3 (75) 5 2 (40) 
Decreased number of mosquito pools 
tested 
4 1 (25) 5 2 (40) 
Decreased number of WNV tests 
performed on human specimens 
5 1 (20) 2 1 (50) 
Other 6 0   
* Yes includes “highly,” “substantially,” “some” and “a little.” 
** Only respondents who had a system and who answered the question either yes or no. 
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Appendix 1: Detailed information on state subgroupings 
 
I. Quartile groupings by size of state and local health populations using 
population estimates based on the 2010, U.S. Census Bureau  (listed in alphabetical 
order) 
 
8.0 to 37.3 Million 
California, Florida, Georgia, Illinois, Michigan, New Jersey, New York, North 
Carolina, Ohio, Pennsylvania, Texas, Virginia 
 
4.5 to 6.9 Million 
Alabama, Arizona, Colorado, Indiana, Louisiana, Maryland, Massachusetts, 
Minnesota, Missouri, South Carolina, Tennessee, Washington, Wisconsin 
 
2,0 to 4.9 Million 
Arkansas, Connecticut, Iowa, Kansas, Kentucky, Mississippi, Nevada, New 
Mexico, Oklahoma, Oregon, Utah 
 
0.6 to 1.9 Million 
Alaska, Delaware, Hawaii, Idaho, Maine, Montana, Nebraska, New Hampshire, 
North Dakota, Rhode Island, South Dakota, Vermont, West Virginia 
 
II. State groupings by cumulative number of WNV cases reported to CDC 2008-
2012 
(listed alphabetically within grouping) 
 
>100 cases 
Arizona, California, Colorado, Illinois, Louisiana, Michigan, Mississippi, New 
York, Ohio, Oklahoma, Texas 
 
30-99 cases 
Alabama, Arkansas, Connecticut, Florida, Georgia, Indiana, Kansas, Maryland, 
Massachusetts, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New 




Idaho, Iowa, Kentucky, North Carolina, South Carolina, Utah, Wyoming  
 
0-9 cases 
Delaware, Hawaii, Maine, Montana, New Hampshire, Oregon, Rhode Island, 
Vermont, West Virginia 
 
III. State groupings by U.S. Department of Health and Human Services (HHS) 
Regions 
[available from URL: http://www.hhs.gov/about/regions] 
(listed alphabetically within region) 
Region 
I    Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, 
     Vermont 
II  New Jersey, New York 
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III  Delaware, Maryland, Pennsylvania, Virginia, West Virginia 
IV Alabama, Florida Georgia, Kentucky, Mississippi, North Carolina, South 
Carolina, Tennessee 
V  Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin 
VI  Arkansas, Louisiana, New Mexico, Oklahoma, Texas 
VII  Iowa, Kansas, Missouri, Nebraska 
VIII  Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming 
IX  California, Arizona, Hawaii, Nevada 
X  Alaska, Idaho, Oregon, Washington 
 
Grouping 
Northeast = I, II, III 
Midwest = V, VII 
Southeast and South central = IV, VI 
Rocky Mountains = VIII 
West and Northwest = IX, X 
 
 
IV. State groupings by amount of FY2012 CDC ELC Cooperative Agreement, 
Arboviral Disease Activity Funding 
Note:  Separate awards to large cities are not included in the total for the state. 
(listed alphabetically within grouping) 
 
Greater than or equal to $300,000 
Arizona, California, Colorado, Mississippi, Nebraska, New York, North Dakota, Texas 
 
$200,000 to $299,000 
Florida, Idaho, Illinois, Maryland, Minnesota, Montana, South Dakota, Tennessee, Utah 
 
$100,000 to $199,999 
Connecticut, Delaware, Georgia, Indiana, Iowa, Kansas, Louisiana, Massachusetts, 
Michigan, Missouri, Nevada, New Hampshire, New Jersey,  New Mexico, North 
Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, 
Virginia, Washington, West Virginia, Wisconsin,  Wyoming 
 
Less than $100,000 
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CSTE Vector-borne Disease Surveillance Capacity Assessment for State 
Health Departments 
 
Characterization of a State Health Department Arbovirus Surveillance Program 
•Please respond for activities, data, and cases that occurred in calendar 
year 2012. 
•Definitions:  
“Your jurisdiction” = your state 
“Your agency” = the state health dept, not county HDs 
“Your program” = the state health dept. WNV/arbovirus or   
communicable disease program 
“WNV/arbovirus surveillance program” = the program within your 
   agency, not county HDs 
 
State: 
Name of respondent: 
Title/Position of respondent: 
Date: 
 
1. Indicate below the number of WNV and other arboviral disease surveillance 
staff—both epidemiology  and laboratory— from ALL funding sources based 
on highest professional degree. These are mutually exclusive categories, so 
place each staff person in only one column. Surveillance staff include those 


























1.0 FTE*     
0.5-0.99 FTE     
<0.50 FTE     
Contractors (not including county HDs)** 
1.0 FTE*     
0.5-0.99 FTE     
<0.50 FTE     
*   a full time position for 6 months would be one 0.5 FTE; 5 full time positions 
each working 20% on WNV would be five  <0.50 FTE (in appropriate column) 
**  contracted positions include a) those based in the state health department but 
hired by another agency, or b) those based in another agency who are funded by 
state/federal funds to support arboviral surveillance (e.g., for mosquito or bird 
surveillance or for laboratory testing).  
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2. Indicate below the number of WNV and other arboviral disease surveillance 
staff—both epidemiology  and laboratory— NOT funded by the CDC 
Epidemiology and Laboratory Capacity (ELC) or Public Health Preparedness 
cooperative agreements based on highest professional degree. These are 


























1.0 FTE*     
0.5-0.99 FTE     
<0.50 FTE     
Contractors (not including county HDs)** 
1.0 FTE*     
0.5-0.99 FTE     
<0.50 FTE     
*   a full time position for 6 months would be one 0.5 FTE; 5 full time positions 
each working 20% on WNV would be five <0.50 FTE (in appropriate column) 
 
3. Indicate below the number of FTE WNV and other mosquito-borne disease 
surveillance staff you have at the state level from ALL funding sources based on 
their surveillance role (include contractors but not county HDs). The total should 
take into account the time contributed by each of the FTEs in Q1. (e.g., if in Q1 
there were 8 epidemiologists each contributing 10% of their time to WNV for 6 
months, you should report 0.4 FTE) 
 
Total # FTE 
epidemiologists 
#  FTE 
laboratory 
staff 









     
 
 
4. Indicate below how many ADDITIONAL FTE staff persons (including 
contractors but not county HDs) are needed at the state level in your state to 
achieve full epidemiology and laboratory capacity* to conduct WNV and other 
mosquito-borne disease surveillance. As above, count a full time seasonal 
position needed for 6 months as 0.5 FTE. 
 
* Full epidemiology and laboratory capacity is defined as: i) ability to complete a 
standard case report form on every suspected/confirmed mosquito-borne 
arboviral disease case and report it to ArboNet; ii) ability to test by IgM for all 
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relevant arboviruses (including dengue) on any CSF or serum specimen 
submitted to the state lab on a suspected case of arboviral disease); and iii) have 
an environmental surveillance system that includes mosquito surveillance to 
routinely monitor arboviral activity in all parts of the state in which there is the 























     
 





5. Does the state health department have adequate access to medical 
entomologist(s) 
- within the public health agency     ___Yes    ____No 
 
- through contract or other formal arrangement with a local college or 
university or other state agency? ___Yes ____No 
 
6. Does the state health department have adequate access to expertise in 
wildlife biology within a state agency? ___Yes ____No 
 
7. Does the state health department have a designated state public health 
veterinarian within your agency? ___Yes ____No 
 
Optional comments to explain response to any of Questions 5-7 (leave space)  
 
…………………………………………………………………………………………… 
8. Please complete the following table concerning the duration of surveillance 






If yes, for how many months each 
year? 
Yes  No 
Human disease    
Equine disease    
Avian mortality    
Mosquito    
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9. What type of surveillance is used in your jurisdiction for WNV-related (check 













Human disease     
Equine disease     




10. For human West Nile neuroinvasive disease surveillance in 2012: 
   a. Did your agency specifically contact by telephone, fax, special mailing, or  
health alert any of the following specialists to encourage reporting and to  
suggest they have a high index of suspicion for arboviral encephalitis? 
Neurologists ____Yes  ____No 
Critical care specialists ____Yes  ____No 
Infectious disease specialists ____Yes  ____No 
Emergency departments ____Yes ____No 
 
   b.  Did your agency require reporting of: 
- hospitalized encephalitis cases of unknown etiology? 
____Yes  ____No 
 
-  hospitalized meningitis cases of unknown etiology? 
____Yes  ____No 
 
   c. Did your agency require in-state laboratories to report CSF and/or 
serologic specimens positive for arboviral infection? 
____Yes  ____No 
 
11. In 2012, in order to count a case of WNV infection as  
confirmed or probable, did your agency require confirmation of commercial –
lab-positive specimens by your public health laboratory or another reference 
laboratory? ____ Yes  ____ No 
 
12. Did your program use the CDC/CSTE National Public Health Surveillance 
System (NPHSS) case definition for neuroinvasive disease to classify cases 
as confirmed or probable or did you use another case definition in your 
jurisdiction? 
____ CDC/CSTE NPHSS case definition used exclusively 
____ A modified case definition specific to my jurisdiction 
 




The following questions pertain to all WNV human disease cases, not just 
neuroinvasive cases.  
 
13.  In 2012 what was the median interval in days between the  
date that a WNV positive human specimen was collected and the date that 
positive laboratory results were reported to the WNV surveillance program? 
____ Days ____Don’t know ____Not applicable (no cases) 
 
14. In 2012 for cases of human disease that were ultimately  
determined to be probable/confirmed, what was the median interval in days 
between the date of onset of the case and the date that the case was 
reported to ArboNET? 
____ Days ____Don’t know ____Not applicable (no cases) 
 
15. In 2012, was end-of-year surveillance (e.g., auditing) done of  
hospital or commercial laboratories to identify unreported human cases of 
WNV? ____Yes  ____No 
 
16. In 2012, was end-of-year surveillance done of hospital discharge data  
to identify unreported human cases of WNV? ____Yes  ____No 
 




17.  For equine West Nile disease surveillance in 2012: 
a. Did your agency have a system in place for reporting cases of 
equine neurologic disease to the state health dept. either directly or 
through another agency (e.g., State Department of Agriculture) from 
veterinarians, veterinary diagnostic labs or other agency labs? 
____ Yes  ____ No  ____ Unk 
 
If no or unknown to Question 17a, please skip to Question 18. 
 
b. If yes, were specimens submitted for diagnostic testing for: 
-  WNV? ____ Yes  ____ No  ____ Unk 
-  other arboviruses? ____Yes  ____ No  ____ Unk 
-  rabies? ____Yes  ____ No  ____ Unk 
 
 
c. How many equine specimens were tested in the public health or other 
state-sponsored laboratory for: 
      -   WNV? ____(#) ____Unk 
      -   other arboviruses? ____ (#) ____Unk 
     -   rabies? ____(#) ____ Unk 
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d. Were temporal-geographic clusters (2 or more cases) of equine 
neurologic disease reported to your agency? 
____Yes ___ No 
 
e. If yes, how many clusters were reported? ____ 
 
f. If yes to (d), did your program or any state agency investigate the 
clusters to determine the cause of the illness? ____Yes  ____ No 
 




18.  For avian West Nile virus infection surveillance in 2012: 
a. Did your agency maintain a database of dead bird  
sightings? ____Yes ____No 
 
If no to Question 18a, skip to question 19. 
 
b. If yes, were specimens submitted for diagnostic testing for WNV? 
____Yes  ____ No 
 
c. If yes, how many specimens were tested for WNV in 2012? ____(#) 
____Unk 
 
d. Where was testing of avian specimens done? ____ State lab 
 
 ____ other state agency lab ____  other lab contracted by the state 
 
e. What strategies did your agency use for collecting and testing dead 
birds? (check relevant box for each in grid below) 
 
Strategy Collecting Testing 
Collect or test all dead birds in an area all season long   
Collect or test all in an area until the first tests positive   
Collect or test all of specified species (e.g., corvids) in an 
area all season long 
  
Collect or test all of specified species in an area until the 
first tests positive 
  
Other (specify below)   
 
 
f. What was the median interval in days between the date that a WNV 
positive dead bird was collected and the date that positive laboratory 









19.  For mosquito-based West Nile Virus surveillance in 2012: 
 
a. Does your agency collect information about mosquito surveillance 
in local jurisdictions or areas of your state? ____Yes  ____ No 
____ Not applicable (no mosquito surveillance in local jurisdictions). 
 
If no to question 19a, please skip to question 19h. 
 
b. Approximately what percentage of the human population in your 
jurisdiction lives in an area covered by mosquito surveillance? ____% 
____ don’t know  
 
c. Do most local health agencies within your jurisdiction conduct 
-adult mosquito surveillance? ____Yes  ____ No  
-larval mosquito surveillance? ____Yes  ____ No  
 
d. For how many trap-nights were adult mosquitoes collected in 2012? 
(e.g., 3 traps in one night = 3 trap-nights) 




f. Concerning mosquito identification when testing for WNV and other  
arboviruses, does your agency either receive reports from local 
laboratories with mosquito species identified and/or does your public 
health laboratory identify the species? 
____Yes  ____ No  ____ don’t know 
 
g. Does your agency either calculate minimum infection rates with 
your mosquito data or receive such data? 
____ Yes  ____ No  ____ don’t know 
 
h. What laboratories performed testing for WNV on mosquito pools 
collected in your state in 2012? (check all that apply) 
____ State public health laboratory or other state-funded laboratory 
 ____ Local health-department laboratory 
 ____ Local mosquito control district (if different from county health dep’t) 
 ____ Mosquito surveillance done, but no testing done on mosquito pools 
 ____ Not applicable (no mosquito surveillance done) 
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i.  For what viruses are mosquito pools routinely tested in addition to 
WNV? 
 ____ EEE 
 ____ SLE 
 ____ California serogroup (LaCrosse, Jamestown Canyon, etc) 
 ____ Other (specify) _________________ 
 ____ Not applicable (no testing done) 
 
j. Did your state public health laboratory or another state-funded  
laboratory perform testing for WNV on mosquito pools in 2008? 
____Yes  ____No 
 
k. If yes to 19j, has the capacity of your state public health laboratory or  
other state-funded laboratory to perform testing for WNV on mosquito  
pools diminished since 2008? ____Yes  ____No 
 
l. If yes to 19k, how has it affected the number of mosquito pools tested for 
WNV? 
____No longer test any pools 
____Test fewer pools than before 
____Other (specify) ___________________________________  
 
 (no Question 19m or 19n) 
 
o. Which agencies in your state monitor for pesticide resistance in  
mosquitos? (if both state and local levels do such monitoring, check both) 
____ State health department and/or other state agency 
____ Local health agencies/mosquito control districts 
____ No monitoring done 
____ Don’t know 
 
p. Does your or another state agency (e.g., Environmental Protection) 
conduct or fund sentinel chicken/bird surveillance for WNV and/or other 
arboviruses? ____ Yes  ____ No 
 




____ Other (specify) ______________________________________ 
 






20.  Which of the following WNV and/or other mosquito-borne disease 
prevention messages and activities did your program use and promote in 
2012? (check all that apply) 
____ the use of DEET-based or other effective repellents 
____ peri-residential source reduction 
____ personal protective measures 
____ notification of adulticiding activities 
____ modification of messages for lower literacy and non-English 
speaking audiences 
 
21. Which of the methods did your program use to provide WNV and/or other 
mosquito-borne disease prevention information in 2012? (check all that 
apply) 
____ press releases to electronic and printed media 
____ public service announcements 
____ passive distribution of informational brochures 
____ active distribution of informational brochures 
____ town, community, or neighborhood meetings 
____ posting information on the home page of your agency’s website 
____ door-to-door outreach in selected locations 
____ participation in community clean-ups 
 
22. The following questions pertain to larviciding for mosquitoes to prevent 
amplification of WNV.  
a.  Has your state ever financially supported or conducted larviciding in local 
jurisdictions for WNV prevention? ____ Yes  ____No 
 
b.  Did your state conduct or financially support larviciding for WNV in at least 
some local jurisdictions in 2012? ___Yes  ____No 
 
c.  Might your state have conducted or financially supported larviciding 
activities in local jurisdictions in 2012 if it had sufficient funding?  ____Yes  
____No  ____ Unk 
d.  Did any local jurisdiction conduct larviciding for WNV in 2012 with its own 
funding? ____Y  ____N ____Unk 
 
23. The following questions pertain to killing adult WNV-infected mosquitoes 
(adulticiding). 
a.  Does your state have a plan for WNV control that includes a threshold 
level of vector mosquito abundance and/or infection rate that would result in a 
recommendation for adulticiding? 
____Yes – have a threshold that does not require concurrent human cases 
____Yes – have a threshold that requires concurrent human cases 
____No – have a plan but there is no specific theshold 
____No – do not have a formal plan for adulticiding in respond to WNV 
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b. Does your state have an emergency fund or a specified emergency funding 
mechanism for adult mosquito control for WNV or other arbovirus outbreak 
control? ____Yes ____No 
 
If yes, please describe: _______________________________________ 
 
Has this fund/funding mechanism ever been used to pay for adulticiding for 
WNV outbreak control? ____Yes ____No 
 
c.  Has the state or a local jurisdiction in your state ever conducted 
adulticiding activities for WNV control?  ____Yes  ____No 
 
If no, why not? (check all that apply) 
____Never had serious outbreak threat 
____Had outbreak threat that reached adulticing threshold but no funding to 
support adulticiding 
____Had outbreak threat that reached adulticiding threshold but no public 
support of spraying 
____Other (specify): ________________________________________ 
 
24. Did your state conduct or provide financial support to local health 
departments in 2012 to conduct adulticiding activities for other mosquito-borne 
diseases such as EEE or dengue? ____ Yes  ____ No 
 
If yes,  for which viruses ____ EEE  ____ dengue ____ other (specify) 
_______ 
If no, would you have provided support if you had the funding?   
____ Not applicable, no outbreak threat 
____ Yes, outbreak threat  but insufficient funding to conduct adulticiding 
 
25. Is there a record of Aedes aegypti mosquitoes being found in your state in 
the past 5 years? ____Yes ____No ____ Don’t know 
 
If yes, do you have a written dengue surveillance and control plan should you 
detect dengue in your jurisdiction? ____Yes ____No 
 





26. To what extent has ELC funding for WNV enhanced your agency’s capacity 



















      
Tick-borne       
Flea-borne       
 
 
27. How have you managed reductions to ELC funding for WNV surveillance in 
the past 5 years: 
 
- Eliminated dead bird surveillance ____Yes ____No ____Not applicable (NA) 
- Reduced (but still maintain some) dead bird surveillance ____Yes ____No 
____NA 
- Decreased the number of mosquito trapping sites ____Yes ____No ____NA 
- Decreased the number of mosquito pools tested for WNV (i.e., only test a 
sample of mosquito pools collected)____Yes ____No ____NA 
- Decreased the number of WNV tests on human specimens performed by the 
state laboratory (i.e., more dependent on commercial labs)  ____Yes ____No 
____NA 
- Other (specify) _______________________________________ 
 





The following questions pertain to the state public health laboratory or 
laboratory contracted by your state to do WNV testing on suspected cases 
of disease in people 
 
28. Does your state public health laboratory have at least some WNV testing 
capacity and or do you contract with a laboratory for arboviral testing services? 
____Yes, have own testing capacity 
____Yes, contract with another laboratory for arboviral testing services 
____No, depend on another state’s or regional or CDC laboratory (specify which 
laboratory) ________________________________ 
 
If you have no state public health laboratory WNV testing capacity, you are 
finished.   
 
 
29. Were all CSF specimens tested for WNV in the state public  
health laboratory also routinely tested for  one or more other arboviruses? 
____ Yes  ____ No 
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If Yes, which arboviruses:  ____ EEE  ____ SLE  ____ WEE 
 ____ LaCrosse  ____ Powassan   
 ____Other (specify) ________________________ 
 
 
30. Please complete the following table concerning testing for WNV by the state 
public health laboratory or a laboratory contracted by the state health dept. in 
your jurisdiction (check boxes as instructed below): 
 









Human        
Equine        
Avian        
Sentinel        
Mosquito        
 
 
31. If your laboratory uses a PRNT test, how is it used ? (check one) 
____ all positive ELISAs 
____ early season and any unusual ELISAs throughout the season 
____ only on equivocal ELISAs 
 
32. If PRNT is not performed in your state public health laboratory, where is 
confirmatory testing performed? (check one) 
____ at CDC 
____ at another state’s public health laboratory 
____ ELISA positives are not confirmed by PRNT 
 
(No Question 33) 
 
34. For each of the following arboviruses, does your laboratory perform any 
testing for them and, if so, what was the total number of CSF and/or serologic 
specimens tested for infection in the state public health laboratory in 2012 
and how many were positive?  
 




Chikungunya     
Colorabo tick fever     
Dengue     
EEE     
Japanese 
encephalitis 
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LaCrosse     
Powassan     
SLE     
WEE     
West Nile virus     
Yellow fever     
Other (specify)     
 
 
35. Is additional training necessary to enable your laboratory staff to test for WNV 
and/or other arboviruses? ____Yes ____No (including not applicable) 
 
If yes, please briefly describe what additional training is needed: 
 



























Appendix 3: CSTE Vector-borne Disease Surveillance Capacity Local Assessment 
 
CSTE Vector-borne Disease Surveillance Capacity Assessment for Local 
Health Departments 
 
Characterization of a Local Health Department WNV and other arboviruses 
Surveillance Program 
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•Please respond for activities, data, and cases that occurred in calendar 
year 2012. 
•Definitions:  
“Your jurisdiction” = your city or county, as applicable 
“Your agency” = the local health department, not the state HD 
“Your program” = the local health dept. WNV, arbovirus or   
communicable disease program 
“WNV/Arbovirus Surveillance program” = the program within your 
   agency 
 
City or County: 
Name of respondent: 
Title/Position of respondent: 
Email of respondent: 
Date: 
May we contact you for follow-up? ____Yes ____No 
 
2. Indicate below the number of WNV and other mosquito-borne disease 
surveillance staff—both epidemiology  and laboratory— of the agencies within 
your jurisdiction regardless of funding source based on highest professional 
degree. Surveillance staff include those who are involved in human, animal 
(e.g., bird, horse) and mosquito surveillance. As the categories below are 
mutually exclusive, please place each staff person in only one column: Also, 


























1.0 FTE*     
0.5-0.99 FTE     
<0.50 FTE     
Contractors (not including the state HD)** 
1.0 FTE*     
0.5-0.99 FTE     
<0.50 FTE     
*   a full time position for 6 months would be one 0.5 FTE; 5 full time positions 
each working 20% on WNV would be five <0.50 FTE (in appropriate column) 
**  contracted positions include a) those based in the local health department but 
hired by another agency, or b) those based in another agency who are funded by 
local or federal funds to support arboviral surveillance specifically for your 




2. Indicate below the number of WNV and other mosquito-borne disease 
surveillance staff—both epidemiology  and laboratory— NOT funded by the CDC 
Epidemiology and Laboratory Cooperative Agreement (ELC) or Public Health 
Preparedness cooperative agreements, either indirectly (through the state) or 
directly based on highest professional degree. As the categories are mutually 


























1.0 FTE*     
0.5-0.99 FTE     
<0.50 FTE     
Contractors (not including state HD) 
1.0 FTE*     
0.5-0.99 FTE     
<0.50 FTE     
*   a full time position for 6 months would be one 0.5 FTE; 5 full time positions 
each working 20% on WNV would be five <0.50 FTE (in appropriate column) 
 
3. Indicate below the number of FTE WNV and other mosquito-borne disease 
surveillance staff you have at your jurisdiction level from ALL funding sources 
based on their surveillance role. The total should take into account the time 
contributed by each of the FTEs in Q1. (e.g., if in Q1 there were 8 
epidemiologists each contributing 10% of their time to WNV for 6 months, you 
should report 0.4 FTE) 
 
Total # FTE 
epidemiologists 
#  FTE 
laboratory 
staff 









     
 
 
4. Indicate below how many ADDITIONAL FTE staff persons (including 
contractors)  are needed in your jurisdiction to achieve full epidemiology and 
laboratory capacity* to conduct WNV and other mosquito-borne disease 
surveillance in an “average” year. As above, count a full time seasonal position 
needed for 6 months as 0.5 FTE.  
 
* Full epidemiology and laboratory capacity is defined as: i) ability to complete a 
standard case report form on every suspected/confirmed mosquito-borne 
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arboviral disease case and report it to ArboNet; ii) ability to test by IgM for all 
relevant arboviruses (including dengue) on any CSF or serum specimen 
submitted to the city/county or state lab on a suspected case of arboviral 
disease); and iii) have an environmental surveillance system that includes 
mosquito surveillance to routinely monitor both larval and adult arboviral activity 
in all parts of your jurisdiction in which there is the potential for human outbreaks 
of arboviral disease based on past experience.  
 


















#  additional FTE 
other surveillance / 
clerical/ 
administrative staff 
     
 




5. Does the your city/county health department have adequate access to 
medical entomologist(s) 
- within the public health agency     ___Yes    ____No 
 
- through contract or other formal arrangement with a local college or 
university or other state/local agency? ___Yes ____No 
 
6. Does the city/county health department have adequate access to expertise in 
wildlife biology within a city/county agency? ___Yes ____No 
 
7. Does the city/county health department have a designated public health 
veterinarian within your agency? ___Yes ____No 
 




8. Please complete the following table concerning the duration of surveillance  for 





surveillance at the 
city/county level? 
If yes, for how many months each 
year? 
Yes  No 
Human disease    
Equine disease    
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Avian mortality    
Mosquito    
 
9. What type of surveillance is used in your jurisdiction for WNV-related (check 













Human disease     
Equine disease     




10. For human West Nile neuroinvasive disease surveillance in 2012: 
   a. Did your agency specifically contact by telephone, fax, special mailing, or  
health alert any of the following specialists to encourage reporting and to  
suggest they have a high index of suspicion for arboviral encephalitis? 
Neurologists ____Yes  ____No 
Critical care specialists ____Yes  ____No 
Infectious disease specialists ____Yes  ____No 
Emergency departments ____Yes ____No 
 
   b.  Did your agency (or state through your agency) require reporting of: 
- hospitalized encephalitis cases of unknown etiology? 
____Yes  ____No 
 
-  hospitalized meningitis cases of unknown etiology? 
____Yes  ____No 
 
   c. Did your agency (or state through your agency) require in-state  
laboratories to report CSF specimens positive for arboviral infection? 
____Yes  ____No 
 
11. In 2012, in order to count a case of WNV infection as  
confirmed or probable, did your agency require confirmation of commercial –
lab-positive specimens by your public health laboratory or another reference 
laboratory? ____ Yes  ____ No 
 
12. Did your program use the CDC/CSTE National Public Health Surveillance 
System (NPHSS) case definition for neuroinvasive disease to classify cases 
as confirmed or probable or did you use another case definition in your 
jurisdiction? 
____ CDC/CSTE NPHSS case definition used exclusively 
____ A modified case definition specific to my jurisdiction 
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Optional comments to explain response to any of Questions 10-12 (leave space)  
 
The following questions pertain to all WNV human disease cases, not just 
neuroinvasive cases.  
 
13.  In 2012 what was the median interval in days between the  
date that a WNV positive human specimen was collected and the date that 
positive laboratory results were reported to your WNV surveillance program? 
____ Days 
 
(no Question 14) 
 
15.  In 2012, was end-of-year surveillance (e.g., auditing) done of  
hospital or commercial laboratories to identify unreported human cases of 
WNV? ____Yes  ____No 
 
16..In 2012, was end-of-year surveillance done of hospital discharge  
data to identify unreported human cases of WNV? ____Yes  ____No 
 




17. For equine West Nile disease surveillance in 2012: 
a. Did your agency have a system in place for reporting cases of 
equine neurologic disease to your health dept. either directly or from 
another agency (e.g., State Department of Agriculture) from veterinarians, 
veterinary diagnostic labs or other agency labs? 
____ Yes  ____ No  ____ Unk 
 
If no or unknown to Question 17a, please skip to Question 18. 
 
b. If yes, were specimens submitted for diagnostic testing for: 
-  WNV? ____ Yes  ____ No  ____Unk 
-  other arboviruses? ____Yes  ____ No  ____ Unk 
-  rabies? ____Yes  ____ No  ____ Unk 
 
 
c. How many equine specimens on horses in your jurisdiction were tested 
in the city/county public health, state or contracted laboratory for: 
      -   WNV? ____(#) ____Unk 
      -   other arboviruses? ____(#) ____Unk 
     -   rabies? ____(#) ____Unk 
 
d. Were temporal-geographic clusters (2 or more cases) of equine 
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neurologic disease reported to your agency? 
____Yes ___ No 
 
e. If yes, how many clusters were reported? ____ 
 
f. If yes to (d), did your program or any city/county agency investigate the 
clusters to determine the cause of the illness? ____Yes  ____ No 
 







18. For avian West Nile Virus infection surveillance in 2012: 
a. Did your agency maintain a database of dead bird  
sightings? ____Yes ____No 
 
If no to Question 18, skip to Question 19.  
 
b. If yes, were specimens submitted for diagnostic testing for WNV? 
____Yes  ____ No 
 
e. If yes, how many specimens were tested for WNV in 2012? ____(#) 
____Unk 
 
d.  Where was testing of avian specimens done? ____  City/county lab  
____ State or other agency lab ____ other lab contracted by the 
city/county 
 
e. What strategies did your agency use for collecting and testing dead 
birds? (check relevant box for each in grid below) 
 
Strategy Collecting Testing 
Collect or test all dead birds in an area all season long   
Collect or test all in an area until the first tests positive   
Collect or test all of specified species (e.g., corvids) in an 
area all season long 
  
Collect or test all of specified species in an area until the 
first tests positive 
  
Other (specify below)   
 
f. What was the median interval in days between the date that a WNV 
positive dead bird was collected and the date that positive laboratory 










19. For mosquito-based West Nile Virus surveillance in 2012: 
 
a. Does your agency collect information for mosquito surveillance? 
____Yes  ____ No 
 
If no to question 19a, please skip to question 19h. 
 
b. Approximately what percentage of the human population in your 
jurisdiction is covered by mosquito surveillance? 
____%  ____ don’t know 
 
c. Does your agency or any other agency  within your jurisdiction conduct: 
-adult mosquito surveillance? ____Yes  ____ No 
-larval mosquito surveillance? ____Yes  ____ No 
 
d. For how many trap-nights were adult mosquitoes collected in 2012? 
(e.g., 3 traps in one night = 3 trap-nights) 
____ # trap-nights ____ don’t know 
 




If yes, how often was trapping done at most of these sites in 2012? 
____ every 7 days 
____ every 14 days 
____ other (specify): __________________ 
____ not applicable (no fixed trapping sites) 
 
 
f. Are mosquitoes trapped in your jurisdiction identified to species? 
____Yes  ____ No  ____ don’t know 
 
g. Does your agency either calculate minimum infection rates with 
your mosquito data or receive such data? 
____ Yes  ____ No  ____ don’t know 
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h. What laboratory performed testing for WNV on mosquito pools collected 
in your jurisdiction in 2012? 
 ____ City/county health-department laboratory 
 ____ Local mosquito control district lab (if different than city/county  
lab) 
____ State public health laboratory or other state-funded laboratory 
____ Mosquito surveillance done, but no testing done on mosquito 
 pools for WNV.  
____ Not applicable (no mosquito surveillance done) 
i. For what viruses are mosquito pools routinely tested in addition to 
WNV? 
 ____ EEE 
 ____ SLE 
 ____ California serogroup (LaCrosse, Jamestown Canyon, etc) 
 ____ Other (specify) _________________ 
 
j. Did your local public health laboratory or another locally-funded  
laboratory perform testing for WNV on mosquito pools in 2008? 
____Yes  ____No 
 
k. If yes to 19j, has the capacity of your public health laboratory or  
other locally-funded laboratory to perform testing for WNV on mosquito  
pools diminished since 2008? ____Yes  ____No 
 
l. If yes to 19k, how has it affected the number of mosquito pools tested for 
WNV? 
____No longer test any pools 
____Test fewer pools than before 
____Other (specify) ___________________________________  
 
m. Does your agency map larval breeding sites? 
____ Yes  ____ No  ____ don’t know 
 
n. Does your agency evaluate adult mosquito control using caged 
mosquitoes to measure kill rates in sprayed areas? 
____Yes  ____ No  ____  Not applicable (no spraying)  ____don’t know. 
 
o. Does your or another local agency monitor for pesticide resistance in  
mosquitoes? 
____Yes  ____ No  ____ don’t know 
 
 
p..  Does your agency conduct or fund sentinel chicken/bird surveillance 
for WNV and/or other arboviruses? ____ Yes  ____ No 





____ Other (specify) ______________________________________ 
 





20. Which of the following WNV and/or other mosquito-borne disease 
prevention messages and activities did your program use and promote in 
2012? (check all that apply) 
____ the use of DEET-based or other effective repellents 
____ peri-residential source reduction 
____ personal protective measures 
____ notification of adulticiding activities 
____ modification of messages for lower literacy and non-English 
speaking audiences 
 
21. Which of the methods did your program use to provide WNV (and other 
mosquito-borne disease) prevention information in 2012? (check all that 
apply) 
____ press releases to electronic and printed media 
____ public service announcements 
____ passive distribution of informational brochures 
____ active distribution of informational brochures 
____ town, community, or neighborhood meetings 
____ posting information on the home page of your agency’s website 
____ door-to-door outreach in selected locations 
____ participation in community clean-ups 
 
22. The following questions pertain to larviciding for mosquitoes to  
prevent amplification of WNV in your jurisdiction.  
a.  Has your city/county ever conducted or financially supported larviciding for 
WNV prevention? ____ Yes  ____No 
 
b.  Did your city/county conduct or financially support larviciding for WNV in at 
least some locations in 2012? ___Yes  ____No 
 
c.  Might your city/county have conducted or financially supported larviciding 
activities in local jurisdictions in 2012 if it had sufficient funding?  ____Yes  
____No  ____ Unk 
 
23. The following questions pertain to killing adult WNV-infected  
mosquitos (adulticiding). 
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a.  Does your city/county have a plan for WNV control that includes a 
threshold level of vector mosquito abundance and/or infection rate that would 
result in a recommendation for adulticiding? 
____ No – no specific local plan, defer to state plan 
____Yes – have a threshold that does not require concurrent human cases 
____Yes – have a threshold that requires concurrent human cases 
____No – have a plan but there is no specific theshold 
____No – do not have a formal plan for adulticiding in response to WNV 
 
b. Does your jurisdiction have an emergency fund or a specified emergency 
funding mechanism for adult mosquito control for WNV or other arbovirus 
outbreak control? ____Yes ____No 
 
If yes, please describe: _______________________________________ 
 
Has this fund/funding mechanism ever been used to pay for adulticiding for 
WNV outbreak control? ____Yes ____No 
 
c.  Has your jurisdiction ever conducted adulticiding activities for WNV 
control?  ____Yes  ____No 
 
If no, why not? (check all that apply) 
____Never had serious outbreak threat 
____Had outbreak threat that reached adulticing threshold but no funding to 
support adulticiding 
____Had outbreak threat that reached adulticiding threshold but no public 
support of spraying 
____ Other (specify): ____________________________________ 
 
24. Did your city/county conduct adulticiding activities for  
other mosquito-borne diseases such as EEE or dengue in 2012?  
____ Yes  ____ No 
 
If yes,  for which viruses ____ EEE  ____ dengue ____ other (specify) 
_______ 
If no, would you have conducted adulticiding if you had the funding?   
____ Not applicable, no outbreak threat 
____ Yes, outbreak threat  but insufficient funding to conduct adulticiding 
 
 
25. Is there a record of Aedes aegypti mosquitoes being found in your jurisdiction 
in the past 5 years? ____Yes ____No ____ Don’t know 
 
If yes, do you have a written dengue surveillance and control plan should you 
detect dengue in your jurisdiction? ____Yes ____No 
 






26. To what extent has ELC funding to either the state or directly to your 
jurisdiction for WNV enhanced your agency’s capacity to conduct surveillance 



















      
Tick-borne       
Flea-borne       
 
 
27. How have you managed reductions to ELC funding for WNV surveillance in 
the past 5 years: 
- Eliminated dead bird surveillance ____Yes ____No ____Not applicable 
(NA) 
- Reduced (but still maintain some) dead bird surveillance ____Yes ____No 
____NA 
- Decreased the number of mosquito trapping sites ____Yes ____No 
____NA 
- Decreased the number of mosquito pools tested for WNV (i.e., only test a 
sample of mosquito pools collected)____Yes ____No ____NA 
- Decreased the number of WNV tests on human specimens performed by 
your local public health or other locally-contracted laboratory (i.e., more 
dependent on commercial labs)  ____Yes ____No ____NA 
- Other (specify) 
_________________________________________________ 
 





The following questions pertain to the local public health laboratory or 
laboratory contracted by your jurisdiction to do arboviral testing on 
suspected cases of disease in people.  
 
28. Do you have a local public health laboratory with WNV testing capacity and/or 
contract with a laboratory for WNV testing services? (check all that apply) 
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____Yes, have own testing capacity 
____Yes, contract with another laboratory for arboviral testing services 
____No, depend on the state laboratory 
____No, depend on other laboratory(specify) ___________________ 
 
If you have no local public health laboratory or do not contract with another 
laboratory to do arboviral testing for you, you are finished.   
 
29.   Were all CSF specimens tested for WNV by your public health laboratory or 
the laboratory with which you contracted on patients in your jurisdiction also 
routinely tested for one or more other arboviruses? ____ Yes  ____ No 
 
If Yes, which arboviruses:  ____ EEE  ____ SLE  ____ WEE ____ 




30. Please complete the following table concerning testing for WNV by your 
public health laboratory or a laboratory contracted by your agency (if not 
applicable, put NA in each box):  
 









Human        
Equine        
Avian        
Sentinel        
Mosquito        
 
 
31. If your laboratory or the one with which you have a contract uses a PRNT test 
for specimens from your jurisdiction, how is it used ? (check one) 
____ all positive ELISAs 
____ early season and any unusual ELISAs throughout the season 
____ only on equivocal ELISAs 
 
32. If PRNT is not performed in your agency’s public health laboratory or the one 
with which you contract, where is confirmatory testing performed? (check 
one) 
____ at CDC 
____ at the state or another state’s public health laboratory 




33. If you have your own city/county public health laboratory, please complete the 
following table re: your arboviral laboratory diagnostic testing capacity in 
2012.  
If you directly received ELC funding in 2012 and provided this data (Table 3 
in the ELC cooperative agreement application), please check here and skip 




Arboviral laboratory diagnostic testing capacity in 2012* 
 
Virus 
ELISA MIA IFA 
PRNT PCR IgM IgG IgM IgG IgM IgG 
 
California serogroup†         
Chikungunya         
Colorado tick fever         
Dengue         
Eastern equine 
encephalitis         
Japanese encephalitis         
Powassan         
St. Louis encephalitis         
Western equine 
encephalitis         
West Nile         
Yellow fever         
 
*Please check boxes for assays that your laboratory currently has the capacity to perform, 
including trained staff and necessary equipment and supplies. 
 
†Such as La Crosse or Jamestown Canyon viruses 
 
ELISA = Enzyme-linked immunosorbant assay 
MIA = Microsphere immunoassay 
IFA = Indirect immunofluorescent assay 
PRNT = Plaque reduction neutralization test 
PCR = Polymerase chain reaction 
IgM = Immunoglobulin M 
IgG = Immunoglobulin G 
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34. For each of the following arboviruses, what was the total number of CSF 
and/or serologic specimens tested for infection for persons in your jurisdiction 
in the city/county public health laboratory or laboratory with which you 
contracted in 2012 and how many were positive?  If had no lab testing 
performed,  
 
Arbovirus Number  tested Number positive 
Chikungunya   
Colorado tick fever   
Dengue   
EEE   
Japanese encephalitis   
LaCrosse   
Powassan   
SLE   
WEE   
West Nile virus   
Yellow fever   
Other (specify)   
 
 
35. Is additional training necessary to enable your laboratory staff to test for WNV 
and/or other arboviruses? ____Yes ____No (including not applicable) 
 
If yes, please briefly describe what additional training is needed: 
 
Optional comments to explain response to any of Questions 28-35 (leave space)  
 
 
 
END 
 
